Anti-TfR1 antibody MAb11-22.1 conjugate for cancer therapy

MaB11-22.1, a monoclonal antibody with high TfR1 affinity, addresses the challenge of universal toxicity by specifically targeting cancer cells, effectively inhibiting their growth with minimal impact on normal cells through selective internalization and conjugation with cytotoxins.

JP2024545136AActive Publication Date: 2024-12-05NORTHEAST PHARMA GRP CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024534304
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-06
Filing Date
2022-12-03
Publication Date
2024-12-05
Estimated Expiration
2042-12-03

AI Technical Summary

Technical Problem

Existing anti-TfR1 antibodies face challenges such as universal antiproliferative activity affecting both cancer and normal cells, leading to toxicity and limited efficacy due to cross-reactivity, necessitating the development of antibodies that specifically target cancer cells with minimal impact on normal cells.

Method used

The development of MAb11-22.1, a monoclonal antibody with high affinity for TfR1, specifically designed to inhibit cancer cell proliferation by internalizing TfR1 and conjugated with a cytotoxin (DM1) to enhance therapeutic efficacy.

Benefits of technology

MaB11-22.1 effectively inhibits the growth of cancer cells, including leukemia and solid tumors, while minimizing toxicity to normal cells by selectively targeting TfR1, demonstrating high specificity and efficacy in preclinical models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024545136000001
    Figure 2024545136000001
  • Figure 2024545136000002
    Figure 2024545136000002
  • Figure 2024545136000003
    Figure 2024545136000003
Patent Text Reader

Abstract

The present invention provides a therapeutic agent for the treatment, prevention, and diagnosis of cancers associated with cells that overexpress transferrin receptor 1 (TfR1) and its variants on the cell surface, including, but not limited to, AML, ALL, lymphoma, multiple myeloma, breast cancer, gastric cancer, glioblastoma, prostate cancer, urothelial cancer (bladder cancer), pancreatic cancer, esophageal cancer, colorectal cancer, ovarian cancer, and liver cancer. The agent is based on the amino acid sequences of the novel light and heavy chain variable regions of MAb11-22.1, an anti-TfR1 monoclonal antibody (mAb), which is highly specific for tumor cells, in the form of an ADC, and can functionally inhibit the proliferation of several human cancer cell lines and the growth of xenograft tumors derived from AML cell lines in mouse models.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present invention relates to the use of antibodies to bind to and modulate the internalization and activity of transferrin receptor 1 (TfR1) and its isoforms in human cancer cells. The invention also relates to antibodies or small molecule conjugates (antibody-drug conjugates, ADCs) for the in vitro, in situ, and / or in vivo diagnosis and / or treatment of mammalian cells or pathological conditions associated with TfR1 and its isoforms. [Background technology]

[0002] Transferrin receptor 1 (TfR1, CD71) is a type II transmembrane glycoprotein consisting of 760 amino acids, linked by two disulfide bonds to form a 180-kDa homodimer, which plays an important role in regulating iron uptake and cell growth (BOMFORD and MUNRO. Hepatology. 5:870-875, 1985). Upon binding of diferric transferrin (Tf) to TfR1 on the cell surface, the holo-Tf-TfR1 complex is internalized by clathrin-coated pits and delivered to acidic endosomes, where the ferric Tf-TfR1 complex undergoes a low-pH-induced conformational change, followed by iron release and transport into the cytoplasm. The apoTf / TfR1 complex (apo-Tf / TfR1) then recycles back to the cell surface, where apoTf (apo-Tf) dissociates from the receptor (WARD. Invest Radiol. 22:74-83, 1987; DANIELS et al. Clin Immunol. 121:144-158, 2006). TfR1 expression is increased in rapidly proliferating cells with a high iron requirement for heme synthesis, such as blood cells, hepatocytes, and keratinocyte precursors, but its expression is reduced or absent in non-dividing cells. TfR1 is overexpressed in primary and metastatic cancer cells derived from lymphocytes, pancreas, stomach, colon, lung, breast, bladder, and skin (GATTER et al. J Clin Pathol.36:539-545,1983; FAULK et al. Lancet.2:390-392,1980; SUTHERLAND et al. Proc Natl Acad Sci USA 78:4515-4519,1981; DANIELS et al. Clin Immunol.121:144-158,2006; JEONG et al. Biochem Biophys Res Commun.471:373-379,2016; PEER et al. Nat Nanotechnol.2:751-760,2007; QIAN et al. Pharmacol Rev.54:561-587,2002; RICHARDSON et al. Biochim Biophys Acta Gen Subj.1790:702-717,2009).Cancer cells are thought to be more sensitive to iron deprivation, so targeting Tf or TfR1 by blocking its binding or interfering with the internalization of the holo-Tf / TfR1 complex causes iron deprivation, resulting in the death of malignant cells.

[0003] The literature over the past 30 years describes many attempts to treat malignant diseases by developing anti-human TfR1 antibodies or TfR1-binding peptides to compete with Tf in receptor binding or preventing internalization (for reviews see TORTORELLA and KARAGIANNIS. J Membr Biol. 247:291-307, 2014; CANDELARIA et al. Front. Immunol. 17 March 2021. doi.org / 10.3389 / fimmu.2021.607692). TROWBRIDGE and LOPEZ (Proc. Natl Acad Sci USA, 79, 1175-1179, 1982; U.S. Patent No. 4,434,156) reported a murine anti-TfR1 antibody, designated 42 / 6, which blocks the binding of Tf to TfR1 by a non-competitive mechanism and inhibits the growth of human T-cell leukemia cell lines in the S phase of the cell cycle in vitro. 42 / 6 was found to be well tolerated by patients in a phase Ia clinical trial, but lack of efficacy occurred due to its murine IgA isotype, which induces human anti-mouse antibodies (HSMS) and is rapidly cleared by the kidney (BROOKS et al. Clin Cancer Res. 1:1259-1265, 1995). MOURA et al. (J Exp Med, 194, 417-425, 2001) reported that 42 / 6 binds to TfR1 with high affinity (K DA more potent neutralizing murine anti-TfR1 IgG2b antibody (A24) has been reported that directly competes with Tf by binding to TfR at a concentration of 2.7 nM (TfR = 2.7 nM), downregulating TfR expression, and inhibiting TfR recycling, thereby inhibiting T cell proliferation. In contrast to 42 / 6, which exerts its antiproliferative effect by inhibiting cells in the S phase of the cell cycle, A24 acts by inducing apoptosis of target cells and inhibited the in vitro growth of adult T-cell leukemia / lymphoma (ATLL), acute myeloid leukemia (AML), and mantle cell lymphoma (MCL) cells (Moura et al. Blood. 103:1838-1845, 2004; CALLENS et al. Leukemia. 22:42-48, 2008; LEPELLETIER. Cancer Res. 67:1145-1154, 2007).

[0004] In recent years, several chimeric, humanized, or fully human antibodies have been developed to overcome the lack of efficacy and HAMA responses in humans. For example, the mouse-human IgG3 chimeric antibody ch128.1 has demonstrated in vivo anticancer activity in cell line-derived xenograft (CLDX) models of human multiple myeloma (MM) and AIDS-related non-Hodgkin's lymphoma (AIDS-NHL) (DANIELS. J Immunother. 34:500-508, 2011; DANIELS-WELLS. J Immunother. 38:307-310, 2015). Its humanized version, hu128.1 (IgG1), is also potent in the AIDS-NHL CLDX model (DANIELS-WELLS. Cancer Res. 80(16 Suppl):5655, 2020). The anti-cancer activity of ch128.1 and hu128.1 appears to be dependent on Fc-mediated antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP). Three fully human neutralizing antibodies of the IgG1 isotype have been described. PPMX-T003 and H7-IgG1 inhibited tumor growth and prolonged mouse survival in various leukemia or lymphoma models (SHIMOSAKI et al. Biochem Biophys Res Commun. 485:144-151, 2017; ZHANG et al. Cancer Res. 77(13 Suppl):5586, 2017). Even more surprisingly, the anti-TFRC developed by NAGAI et al. (Cancer Med.3:108-1099,2014) inhibited the proliferation of oral squamous cell carcinoma (OSCC) cells both in vitro and in vivo (NEIVEYANS et al. MAbs.11:593-605,2019.), suggesting that TfR1 may have potential for use in the treatment of solid tumors in addition to hematopoietic malignancies.

[0005] Due to the ubiquitous expression profile of TfR1 in dividing cells, anti-TfR1 antibodies may have universal antiproliferative activity that is intolerable to cancer patients. Mild to moderate toxicity of anti-TfR1 antibodies to red blood cell (RBC) progenitor cells and myeloid progenitor cells has been reported in animal models (CANDELARIA et al. Front. Immunol. 17 March 2021). While many anti-human TfR1 antibodies, including 42 / 6, have shown promising preclinical results, only CX-2029, an anti-TfR1 antibody-drug conjugate (ADC), has progressed to the clinical stage and demonstrated dose-dependent hematologic toxicity (anemia, neutropenia, and leukopenia) manageable with red blood cell transfusions in a phase I clinical trial (JOHNSON et al. Clin Cancer Res. 27:4521-4530, 2021). Therefore, anti-TfR1 antibodies that specifically target cancer cells and minimize cross-reactivity with normal cells are needed for cancer therapy. Summary of the Invention

[0006] MAb11-22.1 mAb is a monoclonal antibody (IgG1, κ) produced by one of the hybridomas obtained from mice immunized with multiple acute myeloid leukemia (AML) cell lines, and was identified as a specific mAb against human TfR1 expressed on AML and other cancer cells. The affinity between MAb11-22.1 mAb and TfR1 is very high (K D <1×10 -12 M). In vitro assays showed that MAb11-22.1 mAb had a modest inhibitory effect on cancer cell proliferation. In an in vivo study, an antibody-drug conjugate (ADC) of MAb11-22.1 chimeric antibody (MAb11-22.1-S239C-DM1) coupled with mertansine (DM1, N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine) significantly inhibited the growth of OCI / AML2 xenograft tumors.

[0007] The coding sequence for the variable region of the light chain of MAb11-22.1 mAb is shown below in SEQ ID NO:1. 1 gacattgtga tgacacagtc tccatcctcc ctgactgtga cagcaggaga 50 51 gaaggtcact atgagctgca agtccagtca gagtctgtta aatagtggaa 100 101 atcaaaagaa ctacttgacc tggtaccagc agaaaccagg acagcctcct 150 151 aaactgttga tctactgggc atccacttgg gaatctaggg tccctgatca 200 201 cttcacaggc agtggatctg gaacagattt cactctcacc atcagcagtg 250 251 tgcaggctga agacctggca gtctattact gtcagaatga ttatagttat 300 301 cctctcacgt tcggtgctgg gaccaagctg gagctgaaac gggctgatgc 350 351 tgca (SEQ ID NO: 1)

[0008] The translated amino acid sequence of the light chain variable region is predicted as SEQ ID NO: 2 below, with the three antigen-determining regions (CDR1 to CDR3, from left to right) highlighted in bold and underlined. IVMTQSPSSL TVTAGEKVTM SCKSS QSLLN SGNQKNYLT W YQQKPGQPPK LLIY WASTWE SR VPDHFTGS GSGTDFTLTI SSVQAEDLAV YYC QNDYSYP LT FGAGTKLE LKRADAA (SEQ ID NO: 2)

[0009] The coding sequence for the variable region of the heavy chain of MAb11-22.1 mAb is shown below in SEQ ID NO:3. 1 gaggtccagc tgcagcagtc tggacctgag ctggtgaagc ctggggcttc 50 51 agtgaggatt tcctgcaaga cttctggcta caccttcaca aactactata 100 101 tacactggat gaagcagagg cctggacagg gacttgagtg gattggatgg 150 151 atttatcctg gagatggtaa ttctcattac aatgagaagt tcaagggcaa 200 201 gaccacactg actgcagaca aatcctccag cacaggctac atattgctca 250 251 gcagcctgac ctctgaagac tctgcagtct atttctgtac aagagattat 300 301 gataactacg ggggatttgc ttactggggc caagggactc tggtcactgt 350 351 ctct (SEQ ID NO: 3)

[0010] The translated amino acid sequence of the heavy chain variable region is predicted as SEQ ID NO: 4 below, with the three antigen-determining regions (CDR1 to CDR3, from left to right) highlighted in bold and underlined. EVQLQQSGPE LVKPGASVRI SC KTSGYTFT NYYIH WMKQR PGQGLEWIG WI YPGDGNSHYN EKFKG KTTLT ADKSSSTGYI LLSSLTSEDS AVYFC TRDYD NYGGFAY WGQG TLVTVSA (SEQ ID NO: 4)

[0011] The present invention relates to binding agents (defined below) comprising antibodies (defined below), such as monoclonal antibodies, fragments and derivatives thereof, that comprise one or more light chain CDR regions that are at least 70% (e.g., 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99%) identical to the light chain CDR region of the anti-TfR1-specific mAb designated MAb11-22.1, and that comprise a light chain variable region that is at least 70% (e.g., 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99%) identical to SEQ ID NO: 2. Optionally, the heavy chain variable region of the binding agent is at least 70% (e.g., 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99%) identical to SEQ ID NO: 4. The binding agent may comprise a region, such as the light chain CDR1 of MAb11-22.1, that is at least 70% (e.g., 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99%) identical to the sequence QSLLNSGNQKNYLT (SEQ ID NO: 5). The binding agent may comprise a region, such as the light chain CDR2 of MAb11-22.1, that is at least 70% (e.g., 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99%) identical to the sequence WASTWESR (SEQ ID NO: 6). The binding agent may comprise a region, such as the light chain CDR3 of MAb11-22.1, that is at least 70% (e.g., 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99%) identical to the sequence QNDYSYPLT (SEQ ID NO: 7). The binding agent may comprise a region, such as the heavy chain CDR1 of MAb11-22.1, that is at least 70% (e.g., 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99%) identical to the sequence KTSGYTFTNYYIH (SEQ ID NO: 8). The binding agent may comprise a region, such as the heavy chain CDR2 of MAb11-22.1, that is at least 70% (e.g., 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99%) identical to the sequence WIYPGDGNSHYNEKFKG (SEQ ID NO: 9).The binding agent may comprise a region such as the heavy chain CDR3 of MAb11-22.1 that is at least 70% (e.g., 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99%) identical to the sequence TRDYDNYGGFAY (SEQ ID NO: 10).

[0012] This application relates to the treatment of several types of cancers that overexpress TfR1 using MAb11-22.1 and MAb11-22.1-related binding agents (defined below), which are derived from or contain portions at least 70% (e.g., 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99%) identical to one or more of the light and heavy chain CDR sequences of MAb11-22.1. MAb11-22.1 specifically binds to human TfR1 protein with high affinity and induces internalization of the protein.

[0013] The binding agent is preferentially used in the treatment of tumor-related diseases including primary and metastatic cancers, for example, leukemia, lymphoma, multiple myeloma, breast cancer, glioblastoma, prostate cancer, urothelial cancer (bladder cancer), esophageal cancer, colorectal cancer, pancreatic cancer, ovarian cancer, liver cancer, gastric cancer (including gastric squamous cell carcinoma, gastric adenocarcinoma, gastric small cell carcinoma, gastric squamous cell carcinoma, gastric carcinoid tumor, and gastric and duodenal cancer).

[0014] The binder conjugate preferably comprises an antitumor agent, such as a cytotoxin (maytansine or a derivative thereof, auristatin or a derivative thereof, epothilone or a derivative thereof, paclitaxel or a derivative thereof, or a vinca alkaloid compound, or further comprises combretastatin A-4 phosphate, combretastatin A-4 or a derivative thereof, an indole-sulfa compound, a vinca alkaloid compound (vinblastin e), vincristine, vindesine, vinorelbine, vinflunine, vinglycinate, anhydrovinblastine, dolastatin 10 and its analogs, halichondrin B and eribulin, indole-3-oxalylamides, substituted indole-3-oxalylamides, podophyllotoxin, 7-dioxalylamides, Ethylamino-3-(2'-benzoxazolyl)-coumarin (DBC), discodermolide, laulimalide, etc.; DNA topoisomerase inhibitors (camptothecin and its derivatives, mitoxantrone, etc.); mitoguazone; nitrogen mustard analogues (chlorambucil, chromafazine, cyclophosphamide, etc.); cyclophosphamide, estramustine, ifosfamide, mustine, nitromin, melphalan, novembichin, phenamet, phenesterine, prednimustine, trofosfamide, uramustine, etc.);Nitrosoureas (Carmustine, Streptozotocin, Fotemustine, Lomustine, Nimustine, Ranimustine, etc.); Antibiotics (Enediyne antibiotics, Dynemicin, Esperamicin, Neocarzinostatin, Aclacinomycin, Actinomycin) Actinomycin, Anthroamycin, Azaserine, Bleomycin, Actinomycin C, Carabicin, Idarubicin, Carzinophilin, Carminomycin, Actinomycin D, Daunorubicin, Doxorubicin, 6-Diazo-5-oxo-L-norleucine, Adriamycin Adriamycin, Epirubicin, Esorubicin, Idarubicin, Marcellomycin, Mitomycin, Mycophenolic acid, Nogalamycin, Olivomycin, Peplomycin, Bofeimeisu, Puromycin, Adriamycin-Fe, Rodorubicin icin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin, etc.; folic acid analogues (denopterin, methotrexate, pteropterin, trimetrexate, edatrexate, etc.);Purine analogues (Fludarabine, 6-mercaptopurine, Thiamiprine, Thioguanine, etc.); Pyrimidine analogues (Ancitabine, Gemcitabine, Enoxaparin, Azacitidine, 6-azauridine, Carmofur, Cytarabine, Dideoxyuridine, Deoxyfluorouridine, Fluoruridine, etc.); Androgens (Calusterone, Dromostanolone Propionate) propionate, epitiostanol, mepitiostane, testolactone, etc.; adrenocorticotropic hormone compounds (aminoglutethimide, mitotane, trilostane, etc.); trichothecenes (T-2 toxin, verracurin A, roridin A, anguidine, etc.); aziridines (benzodopa, carboco Platinum analogues (such as cisplatin, carboplatin, oxaliplatin, miriplatin, etoposide, etc.); antiandrogens (such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin, etc.); protein kinase and proteasome inhibitors);

[0015] Preferably, the binding agent is conjugated to the antitumor drug via a linker. Conjugation may be performed by linking the sulfhydryl group of the binding agent to the antitumor drug using site-specific conjugation, as described for conjugation of Mertansine (DM1) below. Many other conjugation methods are available.

[0016] In some embodiments, linkers may be composed of flexible residues such as glycine and serine (one example is a repeat of four glycines and one serine, or simply repeated glycine residues) and may be used to bind complexes, allowing adjacent protein domains to move freely relative to each other. If it is desired to maintain distance between domains to prevent them from interacting, a rigid linker is preferred; one example is (repeated): glutamic acid, three alanine residues, and lysine. Another rigid linker is (repeated): any amino acid residue and proline. Linkers may be non-cleavable linkers (e.g., thioether, SMCC, PEG linkers) or cleavable linkers (e.g., valine-citrulline (Val-Cit, VC) dipeptide, glutamic acid-valine-citrulline (Glu-Val-Cit, GVC) tripeptide, and disulfide linkers). U.S. Patent No. 9,310,373, "Molecular conjugates," discloses several hydrazide thiol linkers and the preparation of conjugates using them. U.S. Patent No. 8,518,891 discloses linkers with aminoarylmethyl or aminoheteroaryl moieties. Bifunctional linkers are also described. See U.S. Patent No. 11,040,084.

[0017] Suitable dosage ranges and regimens can be extrapolated from the results of the in vivo and in vitro studies described herein. The binding agents are preferentially delivered as pharmaceutical formulations for therapeutic use, but may also be used for diagnostics, purification, or screening to select other binding agents. [Brief explanation of the drawings]

[0018] The patent or application contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[0019] [Figures 1A-1C] We show that MAb11-22.1 mAb directly binds to AML cell lines but not to healthy human peripheral blood mononuclear cells (PBMCs). [Figure 1A] Fluorescence-activated cell sorting (FACS) assays show that MAb11-22.1 mAb interacted with nine human AML cell lines at the cell surface but not with human PBMCs (left panel). An isotype control antibody was used as a negative control in the assay (right panel). Detection was performed with a 1:800 dilution of fluorescein-labeled AffiniPure goat anti-mouse IgG, Fcγ fragment-specific antibody (anti-Mo IgG Fc-FITC, Jackson ImmunoResearch Laboratories). Assays were performed at 4°C. MFI is mean fluorescence intensity. [Figure 1B] Immunocytochemistry (ICC) images of MAb11-22.1 mAb bound to the surface of NB4 or THP-1 cells (upper panel) are shown, whereas an isotype control antibody did not stain these cells (lower panel). AML cells were fixed to glass slides with cytospin in 4% paraformaldehyde. After antigen retrieval, cells were blocked in PBST containing 1% bovine serum albumin (BSA) and then incubated with primary antibodies for 1 hour, followed by a 1:1000 dilution of peroxidase-conjugated AffiniPure goat anti-mouse IgG (subclasses 1+2a+2b+3), Fcγ fragment-specific antibody (Jackson ImmunoResearch Laboratories). Cells were stained with 3,3'-diaminobenzidine (DAB) and counterstained with hematoxylin. [Figure 1C]Western blots showing that MAb11-22.1 mAb hybridized to a protein band present in whole-cell lysates of ALL (Raji) and AML (NB4, OCI / AML2, and THP-1) cells. The target protein was approximately 250 kDa under nonreducing conditions (left panel) or 110 kDa under reducing conditions (right panel). Chinese hamster ovary (CHO) cell lysates were used as a negative control. β-actin was simultaneously detected with a specific mouse mAb as a sample loading control. Peroxidase-conjugated AffiniPure goat anti-mouse IgG Fcγ at a 1:10,000 dilution was used for detection. [Figures 2A-2D] Figure 1 shows the identification and validation of transferrin receptor 1 (TfR1) as the target of MAb11-22.1 mAb. [Figure 2A] Representative silver-stained SDS-PAGE images of immunoprecipitation (IP) samples obtained by reacting MAb11-22.1 mAb with AML whole-cell lysates. The IP samples were reduced and equally loaded in lanes 1 and 2, and the target band at approximately 110 kDa shown was excised for LC-MS / MS analysis. Eight nanograms of reduced MAb11-22.1 mAb were loaded in lane 4 as a control. Protein bands were detected with the ProteoSilver™ Silver Staining Kit (MilliporeSigma) according to the manufacturer's protocol. MW is a molecular weight marker; HC is the heavy chain; and LC is the light chain. [Figure 2B] Western blots of nonreduced ALL and AML whole cell lysate samples simultaneously probed with MAb11-22.1 mAb and anti-β-actin mAb are shown. In the left lane, 1.2 μg of recombinantly expressed TfR1 extracellular domain (rTfR1-ECD, ACRO Biosciences) was loaded as a positive control, and in the two right lanes, two concentrations (1× and 2×) of CHO cell lysate were loaded as negative controls. Detection was performed with peroxidase-conjugated AffiniPure goat anti-mouse IgG Fcγ at a 1:20,000 dilution. [Figure 2C]Direct interaction of MAb11-22.1 mAb with the extracellular domain of TfR1 was confirmed by ELISA. Plates were coated with 0.1 μg / mL of purified rTfR1-ECD containing a C-terminal 6xHis tag. Mouse anti-6xHis mAb and an isotype control antibody were used as positive and negative controls, respectively. All primary antibodies were serially diluted 3-fold from a starting concentration of 3 μg / mL. Peroxidase-conjugated AffiniPure goat anti-mouse IgG Fcγ was used for detection at a dilution of 1:6,000. [Figure 2D] This figure shows the results of a FACS assay of CHO cells with or without recombinant expression of human TfR1-GFP fusion protein (rTfR1-GFP) on the cell membrane. CHO cells did not react with MAb11-22.1 mAb#1 or #2 (two different purified batches) or a commercially available anti-human TfR1 control mAb (R&D Systems). However, after reconstitution of TfR1 on the cell membrane, MAb11-22.1 mAb#1, #2, and the anti-TfR1 control mAb were able to bind to the cell surface. MAb11-22.1 mAb has higher affinity than the anti-TfR1 control mAb. The secondary antibody used was R-phycoerythrin (R-PE)-labeled AffiniPure goat anti-mouse IgG (subclasses 1+2a+2b+3), an Fcγ fragment-specific antibody (Jackson ImmunoResearch Laboratories), at a dilution of 1:800. [Figure 3A-3C] 1 is a data output from the ForteBio Octet® QK system showing the affinity and kinetics between MAb11-22.1 mAb and rTfR1-ECD. [Figure 3A]Aligned sensorgram traces showing the binding and dissociation curves of MAb11-22.1 mAb binding to 20 nM rTfR1-ECD (left panel) or 300 nM goat anti-mouse (H+L) Fab (positive control, right panel) extracted from raw data by fortebio software. The ForteBio Octet® QK system was equipped with an anti-mouse Fc capture (AMC) biosensor for immobilizing 10 nM or 50 nM MAb11-22.1 mAb. The durations of major steps were: 60 s baseline with kinetic buffer, 450 s immobilization of MAb11-22.1 mAb, 120 s baseline / wash with kinetic buffer, 450 s antigen binding, followed by 3000 s dissociation with kinetic buffer alone. The top curve was for 10 nM mAb, and the bottom curve was for 50 nM mAb. [Figure 3B] Binding kinetics data of MAb11-22.1 mAb at 2.5-fold serial dilutions starting from 20 nM to rTfR1-ECD are shown. Binding occurred rapidly, and no dissociation was detected within the observation period (3000 seconds). [Figure 3C] To verify the reliability of the device, kinetic data of binding of MAb11-22.1 mAb at serial dilutions and a positive control goat anti-mouse IgG(H+L) Fab are shown. [Figure 4] This figure shows the results of a competitive ELISA demonstrating that MAb11-22.1 mAb and transferrin (Tf) bind to different sites on rTfR1-ECD. ELISA plates were coated with 0.1 μg / mL rTfR1-ECD and incubated with an array of five concentrations of purified Tf protein (x-axis) individually mixed with seven concentrations of HRP-conjugated MAb11-22.1 mAb, serially diluted 4-fold starting from 2 μg / mL, or with different concentrations of Tf alone. MAb11-22.1 mAb-HRP bound to rTfR1-ECD in a dose-dependent manner, independent of the presence of Tf. Data represent the mean ± standard deviation (SD) of duplicate samples. [Figures 5A-5C]1 shows FACS results of binding of MAb11-22.1 mAb to PBMCs and bone marrow (BM) cells from healthy adults and to BM cells from AML patients. [Figure 5A] MAb11-22.1 mAb did not bind to normal human PBMCs (Stanford Blood Center) or normal human BM cells (Human Cells, Fremont, CA) regardless of mAb concentration. An isotype control antibody served as a negative control. mAbs were serially diluted 8-fold starting at 20 μg / mL and detected with anti-mouse IgG Fc-FITC diluted 1:800. [Figure 5B] MAb11-22.1 mAb shows dose-dependent binding to BM cells from AML patients. [Figure 5C] Scatter plots of PBMCs and BM cells stained with different mAbs. The cutoff values ​​for determining whether a cell surface marker is positive or negative are indicated by solid lines, dividing the graph into four quadrants. The presence of stem cells in the BM sample was confirmed by FITC-labeled mouse anti-human CD34 mAb (Miltenyi, Cambridge, MA), which is specific for hematopoietic stem cells (lower left panel). MAb11-22.1 mAb and isotype control antibodies stained a small proportion of BM cells due to their adhesive nature. [Figure 5D] Erythrocytes present in PBMC and BM cell populations stained with anti-human CD233-PE mAb (Miltenyi) did not react with MAb11-22.1 mAb or isotype control antibody. [Figure 5E] Erythrocytes and erythroblasts present in PBMC or BM cell populations stained with anti-human CD235a-PE (Miltenyi) did not react with MAb11-22.1 mAb or isotype control antibody. [Figures 6A-6C] This shows the results of an internalization assay of MAb11-22.1 mAb using cancer cell lines. [Figure 6A]The fluorescence intensity on the cell surface of three leukemia cell lines (OCI / AML2, NB4, and Raji) individually stained with MAb11-22.1 mAb, mouse anti-human CD20 mAb, or an isotype control antibody under different conditions in a FACS assay is compared. Cells were incubated with each mAb for 1 hour at 4°C, then washed with cold PBS and incubated in medium at 4°C or 37°C. Cell staining was performed with anti-Mo IgG Fc-FITC for 30 minutes, 1 hour, and 2 hours, respectively. At 4°C, MAb11-22.1 mAb bound to the surface of two AML cell lines in a dose-dependent manner, but did not bind to Raji cells and was immediately internalized upon transfer to 37°C (left panel). An anti-CD20 mAb that interacted with Raji cells but not AML cells was partially internalized by Raji cells at 37°C (middle panel). An isotype control antibody that does not bind to either cell line was used as a negative control (right panel). [Figure 6B] Representative fluorescence images of MAb11-22.1 mAb binding to and internalization by the OCI / AML2 cell line. Cells in duplicate 96-well culture plates were incubated with different concentrations of CF488-labeled MAb11-22.1 mAb or CF488-labeled isotype control antibody in DMEM medium for 1 hour at 4°C, followed by washing with ice-cold PBS to remove the mAb. Cells in one plate were resuspended in ice-cold PBS for imaging at 400x magnification using a Keyence fluorescence microscope, while cells in a duplicate plate were resuspended in warm SFM and incubated at 37°C for 1 hour to allow for mAb internalization. MAb11-22.1 mAb-CF488 bound to the surface of OCI / AML2 cells at 4°C but was primarily internalized after 1 hour of incubation at 37°C. As a control, CF488-labeled isotype control mAb did not stain or was internalized by the cells (right panel). All images were taken with the same settings. Scale bar represents 100 μm. [Figure 6C]Representative images showing the dose-dependent increase in binding and internalization of MAb11-22.1 mAb-CF488 by MDA-MB-231 cells. The assay procedure was the same as in Figure 6B, except that a higher concentration of mAb (5 μg / mL) was used. At 4°C, MAb11-22.1 mAb-CF488 was not only localized on the surface of MDA-MB-231 cells but also present intracellularly, indicating a high propensity for MAb11-22.1 mAb-CF488 internalization by the MDA-MB-231 cell line. After 1 hour of incubation at 37°C, most of MAb11-22.1 mAb-CF488 was internalized. CF488-labeled isotype control mAb-CF488 did not stain or enter the cells (right panel). Images were taken at 400x magnification with the same exposure time. The scale bar represents 100 μm. [Figure 7] Figure 1 shows the partial inhibitory effect of MAb11-22.1 mAb on the proliferation of OCI / AML2 cells. Cells (2 x 104 cells / mL) were cultured in a humidified 5% CO2 atmosphere at 37°C in the presence of 100 μg / mL of MAb11-22.1 mAb or an isotype control antibody. Cell viability, as reflected by absorbance at 450 nm (OD450), was monitored every 24 hours by treatment with 10 μL of CCK-8 solution for 4 hours. Data represent the mean ± SD of three replicate samples. *P<0.05. [Figure 8A-8B] 1 is a data output from the ForteBio Octet® QK system showing the affinity and kinetics between MAb11-22.1 chimeric antibody (cAb) and rTfR1-ECD. [Figure 8A]Fitting views and data tables of the association and dissociation curves for the binding kinetics between MAb11-22.1 cAb and rTfR1-ECD at 2.5-fold serial dilutions (50, 20, 8, 3.2, and 1.28 nM) are shown. The Octet QK system was equipped with an anti-human Fc capture (AHC) biosensor to immobilize 50 nM or 10 nM MAb11-22.1 cAb. The durations of the major steps were: baseline with kinetic buffer for 60 s, immobilization of MAb11-22.1 cAb for 450 s, baseline / wash with kinetic buffer for 120 s, binding of antigen to immobilized MAb11-22.1 cAb for 450 s, followed by dissociation with kinetic buffer for 3600 s. The KD of MAb11-22.1 cAb and rTfR1-ECD was less than 1 pM, as no decay of the binding signal was detected during the period allowed for dissociation. [Figure 8B] Fitting view of the kinetic analysis of the positive control goat anti-human (H+L) Fab for 3-fold serial dilutions (300, 100, 33.3, 11.1, and 3.7 nM) in binding to 50 nM MAb11-22.1 cAb. The calculated KD was 2.18 nM. [Figure 9] This is a bar graph showing the effect of MAb11-22.1 cAb and an isotype control antibody with or without the S239C mutation on the proliferation of various cancer cell lines in vitro. OCI / AML2, Raji, HCC38, and MDA-MB-231 cell lines were cultured with individual antibodies at optimal doses for 5 days and then analyzed by CCK-8 assay. Two doses (100 and 300 μg / mL) of MAb11-22.1 cAb (hatched bars) and MAb11-22.1-S239C cAb (gray bars) were treated with DM1 and indicated by a "+" sign below the x-axis, while antibodies without DM1 treatment are indicated by a "-" sign. A non-binding isotype control antibody (white bars) reflected the baseline proliferation of each cell line. Data represent the mean ± SD of triplicate samples. [Figure 10]This figure shows the in vivo efficacy of MAb11-22.1-S239C-DM1 against tumor growth in an OCI / AML2 cell line-derived xenograft (CLDX) mouse model. MAb11-22.1-S239C-DM1 was injected intraperitoneally (ip) at 10 mg / kg (low dose, n = 5) or 20 mg / kg (high dose, n = 6) on a Q4 × 7 schedule (days 0 to 24). A negative control group (n = 5) received an isotype control antibody (without the S239C mutation) treated with DM1 at 20 mg / kg / Q4 × 7 / ip. Tumor volumes were measured every 4 days. The left panel plots tumor volumes for individual mice in each group, and the right panel compares mean tumor volumes ± SD between different groups. From day 16 after four antibody treatments, the mean tumor volume of the low-dose group was significantly different from that of the isotype control DM1 group (*P<0.05). DETAILED DESCRIPTION OF THE INVENTION

[0020] The singular forms "a / an" and "the" are understood to include the plural unless the context clearly dictates otherwise. Monoclonal antibodies are sometimes referred to as "mAbs." The singular and plural forms of the terms "binding agent" and "antibody" are used interchangeably.

[0021] Binding agents of the invention include MAb11-22.1-like or MAb11-22.1-derived antibodies, antibody fragments, fusion proteins, or antibody-derived or engineered chimeric antibody receptors (CARs) that contain a single-chain variable fragment (scFv) fused to an intracellular signaling domain, e.g., the zeta chain of CD3 (CD3ζ). CARs are preferably expressed in CAR immune effector cells, including, but not limited to, T cells, NK cells, and macrophages.

[0022] The term "binding agent" includes antibodies (both of which are used interchangeably in the plural), which are immunoglobulin molecules capable of binding to a target antigen, e.g., an antigen on a gastric cancer cell, via at least one antigen recognition site located in the variable region of the immunoglobulin molecule. As used herein, the term "antibody" includes not only intact (i.e., full-length) polyclonal or monoclonal antibodies, but also antigen-binding fragments thereof (Fab, Fab', F(ab')2, Fv, Fd, rIgG, single-chain (scFv), or sc(Fv)2), variants thereof, fusion proteins containing antibody portions, humanized antibodies, chimeric antibodies, diabodies, multispecific antibodies (e.g., bispecific antibodies), single-domain antigen-binding (SDAB) molecules, VH or VL domains, or VHH domains, and any other modified configuration of an immunoglobulin molecule containing an antigen recognition site of the required specificity, including glycosylation variants of antibodies, amino acid sequence variants of antibodies, and covalently modified antibodies. Antibody-drug conjugates are also included.

[0023] Antibodies include antibodies of any class, such as IgD, IgE, IgG, IgA, or IgM (or subclasses thereof), and antibodies need not be of any particular class. Immunoglobulins may be assigned to different classes depending on the antibody amino acid sequence of the constant domain of their heavy chains. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and some of these classes are further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2.

[0024] The antibodies described herein may be murine, rat, human, or of any other origin (including chimeric or humanized antibodies, such as those described in U.S. Pat. No. 7,317,091 B2, including such antibodies generated by affinity maturation). In some examples, the antibodies comprise a modified constant region, e.g., an immunologically inert constant region that does not induce complement-mediated lysis or stimulate antibody-dependent cell-mediated cytotoxicity (ADCC). ADCC activity may be assessed by the methods disclosed in U.S. Pat. No. 5,500,362.

[0025] Humanized antibodies refer to forms of non-human (e.g., murine) antibodies that are specific chimeric immunoglobulins, immunoglobulin chains, or antigen-binding fragments thereof that contain minimal sequence derived from non-human immunoglobulin. Most often, humanized antibodies are human immunoglobulins (recipient antibodies) in which residues from a complementarity-determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, or rabbit having the desired specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences, but are included to further refine and optimize antibody performance. Generally, humanized antibodies will comprise substantially all of at least one, and typically two, variable domains, with all or substantially all CDR regions corresponding to those of a non-human immunoglobulin and all or substantially all FR regions corresponding to those of a human immunoglobulin consensus sequence. A humanized antibody optimally comprises at least a portion of an immunoglobulin constant region or domain (Fc), typically at least a portion of a human immunoglobulin constant region. The antibody may have a modified Fc region as described in International Patent Publication WO 99 / 58572. Other forms of humanized antibodies have one or more CDRs (one, two, three, four, five, and / or six) that are altered relative to the original antibody. Humanized antibodies may also be subjected to affinity maturation. See Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988).

[0026] In another example, the antibodies described herein are chimeric antibodies, which may comprise heavy and light chain constant regions from a human antibody. See, e.g., Morrison et al. (1984) Proc. Natl. Acad. Sci. USA 81, 6851; Neuberger et al. (1984) Nature 312, 604; Takeda et al. (1984) Nature 314:452. A chimeric antibody refers to an antibody having a variable region or a portion of a variable region from a first species and a constant region from a second species. Typically, in these chimeric antibodies, both the light and heavy chain variable regions mimic the variable regions of antibodies from a certain mammal (e.g., a non-human mammal such as a mouse, rabbit, or rat), and the constant regions are homologous to sequences of antibodies from another mammal, such as a human. In some embodiments, amino acid modifications may be made in the variable and / or constant regions. See U.S. Patent No. 4,816,567.

[0027] The "percent identity" of two amino acid sequences may be determined mathematically by counting and comparing against shorter sequences described or claimed herein, or by utilizing the algorithm of Karlin and Altschul Proc. Natl. Acad. Sci. USA 87:2264-68, 1990, as modified in Karlin and Altschul Proc. Natl. Acad. Sci. USA 90:5873-77, 1993. Such an algorithm is incorporated into the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. J. Mol. Biol. 215:403-10, 1990. BLAST protein searches may be performed with the XBLAST program (score=50, wordlength=3) to obtain amino acid sequences homologous to a protein molecule of interest. When gaps exist between the two sequences, Gapped BLAST may be used as described in Altschul et al., Nucleic Acids Res. 25(17):3389-3402, 1997. When using BLAST and Gapped BLAST programs, the default parameters of the corresponding programs (e.g., XBLAST, NBLAST) may be used.

[0028] (Preparation of binder) Many methods have been developed to generate chimeric, humanized, or human antibodies for in vivo therapeutic use in humans. The most commonly used method is to generate a murine mAb using hybridoma technology and then humanize the mAb by converting the VH and VL domains and framework regions of the constant domains of the mAb to the homologous human framework regions of the human VH and VL domains and constant regions of the desired human gamma immunoglobulin isotype and subclass. See U.S. Patent No. 5,225,539.

[0029] Monoclonal antibodies may be produced by conventional hybridoma techniques (Kohler et al., Nature, 256:495 (1975)). In the hybridoma technique, a mouse or other suitable host animal, such as a hamster or rabbit, is immunized as described above to elicit lymphocytes that produce, or are capable of producing, antibodies that specifically bind to the protein used for immunization. Alternatively, lymphocytes may be immunized in vitro.

[0030] To produce monoclonal antibodies, immune cells are collected from a mammal immunized with an antigen, and the serum is examined for an increase in the level of the desired antibody as described above, followed by cell fusion. The immune cells used for cell fusion are preferably obtained from the spleen. Other preferred parent cells to be fused with the above immune cells include, for example, mammalian myeloma cells, more preferably myeloma cells with acquired properties that allow for drug-mediated selection of fused cells.

[0031] Preferred myeloma cells are those that fuse efficiently, can be used for stable high-level antibody production by selected antibody-producing cells, and are sensitive to media such as HAT medium. Among these, mouse myeloma cell lines such as cell lines derived from MOPC-21 and MPC-11 mouse tumors (available from the Salk Institute Cell Distribution Center, San Diego, California, USA) and SP-2 cells (available from the American Type Culture Collection, Rockville, Maryland, USA) are preferred. Human myeloma cell lines and mouse-human heteromyeloma cell lines have also been described for use in the production of human monoclonal antibodies (Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)).

[0032] The immune cells and myeloma cells may be fused according to known methods, such as those described by Milstein et al. (Galfre et al., Methods Enzymol. 73:3-46, 1981). Lymphocytes are fused with myeloma cells using an appropriate fusing agent, such as polyethylene glycol, to form hybridoma cells (Goding, Monoclonal Antibodies: Principles and Practice, pp. 59-103 (Academic Press, 1986)). Hybridomas obtained by cell fusion may be selected by culturing in a standard selection medium, such as HAT medium (a medium containing hypoxanthine, aminopterin, and thymidine). Cell culture is typically continued in HAT medium for several days to several weeks, allowing enough time for all cells except the desired hybridoma (unfused cells) to die. Hybridoma cells producing the desired antibody are then screened and cloned by standard limiting dilution.

[0033] The hybridoma cells thus generated are seeded and grown in an appropriate medium. The medium preferably contains one or more substances that inhibit the growth or survival of unfused parent myeloma cells. For example, if the parent myeloma cells lack hypoxanthine guanine phosphoribosyltransferase (HGPRT or HPRT), the hybridoma medium typically contains hypoxanthine, aminopterin, and thymidine (HAT medium), which inhibit the growth of HGPRT-deficient cells. The medium in which the hybridoma cells are grown is assayed for the production of monoclonal antibodies against the antigen. Preferably, the binding specificity of the monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or an in vitro binding assay. Absorbance measurements in enzyme-linked immunosorbent assays (ELISAs), enzyme immunoassays (EIAs), radioimmunoassays (RIAs), and / or immunofluorescence assays can be used to measure the antigen-binding activity of the antibodies.

[0034] After hybridoma cells producing antibodies of the desired specificity, affinity, and / or activity are identified, the clones may be subcloned by limiting dilution and grown by standard methods (Goding, Monoclonal Antibodies: Principles and Practice, pp. 59-103 (Academic Press, 1986)). Suitable media for this purpose include, for example, D-MEM or RPMI-1640 medium. The monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures, such as protein A Sepharose, hydroxyapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography. Additionally, the hybridoma cells can be grown in vivo as ascites tumors in the peritoneal cavity of an animal, e.g., a mouse.

[0035] The obtained monoclonal antibodies may be purified, for example, by ammonium sulfate precipitation, a protein A or protein G column, DEAE ion exchange chromatography, or an affinity column to which the protein of the present invention binds.

[0036] The monoclonal antibodies obtained in this manner may also be produced recombinantly using genetic engineering techniques (see, for example, Borrebaeck CAK and Larrick JW, Therapeutic Monoclonal Antibodies, published in the United Kingdom by MacMillan Publishers LTD, 1990). Recombinant antibodies may be produced by cloning antibody-encoding DNA from antibody-producing hybridomas or immune cells such as immune lymphocytes, inserting it into an appropriate vector, and introducing it into host cells. Recombinant techniques are described in the following documents: Specifically, Sambrook et al.,MOLECULAR CLONING:A LABORATORY MANUAL,Second edition,Cold Spring Harbor Laboratory Press,1989,and Third edition,2001;Ausubel et al.,CURRENT PROTOCOLS IN MOLECULAR BIOLOGY,John Wiley &Sons,New York,1987 and periodic updates;the series METHODS IN ENZYMOLOGY, Academic Press, San Diego; Kontermann and Dubel, ANTIBODY ENGINEERING, Springer Lab manual, Springer-Verlag Berlin Heidelberg, 2001).

[0037] When the resulting antibodies are administered to humans for therapeutic purposes, human or humanized antibodies are preferred to reduce immunogenicity. For example, a transgenic animal having a human antibody gene repertoire can be immunized with an antigen selected from whole cells or human cell proteins or their lysates. Antibody-producing cells from the animal can then be collected and fused with myeloma cells to obtain hybridomas from which human antibodies against the antigen can be produced. Alternatively, antibody-producing immune cells, such as immune lymphocytes, can be immortalized with oncogenes and used to produce monoclonal antibodies.

[0038] DNA encoding monoclonal antibodies can be readily isolated and sequenced using conventional techniques (e.g., by using oligonucleotide probes capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). Hybridoma cells serve as a preferred source of such cDNA. Once isolated, the DNA may be placed into an expression vector and then transfected into host cells such as E. coli cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin proteins, to produce the monoclonal antibody in the recombinant host cells. Review articles on recombinant expression of antibody-encoding DNA in bacteria include Skerra et al., Curr. Opinion in Immunol., 5:256-262 (1993); Pluckthun, Immunol. Rev., 130:151-188 (1992).

[0039] The DNA encoding the antibodies produced by the hybridoma cells described above may be genetically modified using conventional techniques to produce genetically engineered antibodies. Genetically engineered antibodies, such as humanized antibodies, chimeric antibodies, single-chain antibodies, diabodies, bispecific antibodies, and multispecific antibodies, may be produced using conventional recombinant techniques. The DNA may then be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains to replace the homologous murine sequences (Morrison et al., (1984) Proc. Nat. Acad. Sci. 81:6851), or by covalently linking all or part of the coding sequence for a non-immunoglobulin polypeptide to the immunoglobulin coding sequence. These methods may produce genetically engineered antibodies, such as chimeric or humanized antibodies, that have the binding specificity of a target antigen.

[0040] Alternatively, certain transgenic animals (e.g., mice) can produce a full repertoire of human antibodies upon immunization in the absence of endogenous immunoglobulin production. For example, the antibody heavy chain joining region (J) in chimeric and germline mutant mice can be expressed in vivo. HIt has been described that homozygous deletion of the .gamma.) gene completely inhibits endogenous antibody production. Transfer of human germline immunoglobulin gene arrays into such germline mutant mice results in the production of human antibodies upon antigenic stimulation. See, e.g., Jakobovits et al., Proc. Natl. Acad. Sci. USA, 90:2551 (1993); Jakobovits et al., Nature, 362:255-258 (1993); Bruggermann et al., Year in Immuno., 7:33 (1993). See also transgenic mice (Xenomouse) available from Amgen, Inc. (Fremont, CA), HuMAb-Mouse®, and TC Mouse™ available from Medarex, Inc. (Princeton, NJ). In another alternative embodiment, antibodies may be produced recombinantly using phage display technology. See, e.g., U.S. Pat. Nos. 5,565,332; 5,580,717; 5,733,743; 6,265,150; Winter et al., (1994) Annu. Rev. Immunol. 12:433-455; (Hoogenboom et al., J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581-597 (1991)). Alternatively, human antibodies and antibody fragments may be produced in vitro, from immunoglobulin variable (V) domain gene repertoires from unimmunized donors, using phage display technology (McCafferty et al., (1990) Nature 348:552-553).

[0041] F(ab')2 fragments can be produced from intact antibodies by digestion with pepsin or other proteins (see, e.g., Morimoto et al., Journal of Biochemical and Biophysical Methods 24:107-117 (1992) and Brennan et al., Science 229:81 (1985)). Fab fragments can be generated by reducing the disulfide bonds of F(ab')2 fragments. Currently, such fragments can be produced directly by recombinant host cells. For example, antibody fragments can be isolated from antibody phage libraries. Alternatively, F(ab')2-SH fragments can be directly recovered from E. coli and chemically coupled to form F(ab')2 fragments (Carter et al., Bio / Technology 10:163-167 (1992)). Alternatively, F(ab')2 fragments can be directly isolated from recombinant host cell culture.

[0042] U.S. Pat. No. 5,932,448 discloses the production of bispecific antibodies with Fab' portions joined by a leucine zipper, U.S. Pat. No. 7,538,196 discloses the production of bispecific antibodies in which the portions are joined by a linker, and U.S. Pat. No. 8,148,496 discloses multispecific Fv antibody constructs having at least four variable domains connected to each other via peptide linkers.

[0043] U.S. Patent Publication No. 20170335281 describes the generation of genetically engineered T cells expressing CARs containing an antigen-binding domain that binds to a cancer-associated antigen. Similar general techniques may be used to engineer T cells or other immune effector cells to express one or more of CDR1, CDR2, and CDR3 of MAb11-22.1 as an antigen-binding domain for cancer therapy. The antigen-binding domain of the CAR polypeptide molecule may comprise any antibody, antibody fragment, scFv, Fv, Fab, F(ab')2, single-domain antibody (SDAB), VH or VL domain, or VHH domain.

[0044] Single domain antibody (sdAb) molecules are disclosed in International Patent Publication No. WO9404678 and Hamers-Casterman, C. et al. (1993) Nature 363:446-448. sdAb molecules are naturally occurring single domain antigen-binding molecules known as heavy chains devoid of light chains. In one type of sdAb, the variable domain is derived from a heavy chain molecule that naturally lacks light chains, which may be derived from Camelidae species, such as camel, llama, dromedary, alpaca, or guanaco. Other species outside of Camelidae may also produce heavy chain molecules that naturally lack light chains. sdAb molecules may be recombinant, CDR-grafted, humanized, camelized, deimmunized, and / or generated in vitro (e.g., selected by phage display).

[0045] Any of the above binding agents can be used in antibody-drug conjugates (ADCs) to target cancer cells by conjugating them with cytotoxins against cancer cells. See U.S. Patent No. 9,764,041; U.S. Patent Publication No. 20170151343.

[0046] (High-affinity antibody mutants) Antibodies having variants of the sequences described herein are within the scope of the invention. One type of variant is the high affinity variant described below.

[0047] Antibodies should be humanized with retention of high affinity for the antigen and other favorable biological properties. To achieve this goal, according to a preferred method, humanized antibodies are generated by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are publicly available. Computer programs are available that display and illustrate probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the function of the candidate immunoglobulin sequence, i.e., residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this way, FR residues from the recipient and import sequences can be selected and combined to achieve desired antibody characteristics, such as increased affinity for the target antigen.

[0048] Examples of framework region residues to be modified include those that directly bind non-covalently to the target (Amit et al. Science 233:747-753(1986)), residues that interact with or influence the conformation of the CDRs (Chothia et al. J. Mol. Biol. 196:901-917(1987)), and / or residues involved in the VL-VH interface (European Patent No. EP 239400 B1). In certain embodiments, modifications to one or more of these framework region residues result in an improvement in the binding affinity of the antibody to the target of interest.

[0049] Nucleic acid molecules encoding amino acid sequence variants are generated by a variety of methods known in the art, including, but not limited to, oligonucleotide-mediated (or site-directed) mutagenesis, polymerase chain reaction (PCR) mutagenesis, and cassette mutagenesis of previously generated mutant or non-mutant forms of the species-dependent antibody. A preferred method for generating variants is oligonucleotide-mediated synthesis. In certain embodiments, antibody variants have only a single hypervariable region residue substituted, e.g., from about 2 to about 15 hypervariable region substitutions.

[0050] One method for generating libraries of variants is oligonucleotide-mediated synthesis. Three oligonucleotides, each approximately 100 nucleotides long, may be synthesized across the entire light or heavy chain variable region. Each oligonucleotide may contain (1) a 60-amino acid stretch generated by the triplet (NNK).sub.20 (where N is any nucleotide and K is G or T) and (2) approximately 15-30 nucleotide overlaps at each end with the next oligo or vector sequence. When these three oligonucleotides are annealed in a PCR reaction, the polymerase fills in the opposite strand to generate a complete double-stranded heavy or light chain variable region sequence. The number of triplets may be adjusted to any length, and their positions in the oligonucleotides may be selected to replace only amino acids within specific CDR or framework regions. By using (NNK), all 20 amino acids are possible at each position in the encoded variant. Overlapping sequences of 5 to 10 amino acids (15 to 30 nucleotides) are not replaced, but may be selected to fit within the framework stacking region, or may be replaced in a single synthetic round or in subsequent synthetic rounds. Methods for synthesizing oligonucleotides are well known in the art and are commercially available. Methods for generating antibody variants from these oligonucleotides are also well known in the art, such as PCR.

[0051] Libraries of heavy and light chain variants that differ at random positions in their sequence may be constructed in any expression vector, such as bacteriophage, with each vector containing DNA encoding a specific heavy and light chain variant.

[0052] After the antibody variants are produced, the biological activity of the variants relative to the parent antibody is determined. As mentioned above, this involves determining the binding affinity of the variants for a target. There are many high-throughput methods for rapidly screening the binding ability of antibody variants for a target of interest.

[0053] One or more antibody variants selected by this initial screening may then be screened to obtain binding affinities superior to those of the parent antibody. One common method for determining binding affinity is to evaluate the association and dissociation rate constants using a BIAcore surface plasmon resonance system (BIAcore, Inc.). A biosensor chip is activated for covalent binding of the target according to the manufacturer's instructions (BIAcore). The target is then diluted and injected onto the chip, obtaining a signal in response units (RU) of the immobilized material. Because the signal in RU is proportional to the mass of the immobilized material, this represents the range of densities of the immobilized target on the matrix. The dissociation data are fitted to a one-site model to obtain the K off The pseudo-first-order rate constant (Ks) was calculated for each binding curve and plotted as a function of protein concentration to obtain the K on ±SD (standard error of fitting). The equilibrium dissociation constant K d K off / K on Calculate the equilibrium dissociation constant K D K off Since it is inversely proportional to the binding rate (K on ) is constant for all variants, the affinity improvement can be estimated.

[0054] Optionally, the resulting high affinity candidates may be subjected to one or more additional biological activity assays, e.g., as tested in the assays described in the Examples below, to confirm that the antibody variants with improved binding affinity still retain the desired therapeutic properties. The optimal antibody variants will retain the ability to bind to the target with significantly higher binding affinity than the parent antibody.

[0055] The antibody variants thus selected may often be further modified, depending on the intended use of the antibody. Such modifications may involve further alterations of the amino acid sequence, fusion with heterologous polypeptides, and / or covalent modifications as described in more detail below. For example, any cysteine ​​residues not involved in maintaining the proper conformation of the antibody variant may be substituted, generally with serine, to improve the oxidative stability of the molecule and prevent aberrant crosslinking. Conversely, cysteine ​​bond(s) may be added to the antibody to improve its stability (particularly where the antibody is an antibody fragment such as an Fv fragment).

[0056] (formulation) After a suitable antibody is produced, it may be prepared as a formulation for administration to a subject. Lyophilized formulations are preferred, and for this purpose, the first step involves preparing a pre-lyophilized formulation. The amount of antibody in the pre-lyophilized formulation is determined taking into account the desired dosage, administration method, etc. Proteins are generally present in a solution. For example, proteins may be present in a pH buffer solution with a pH of about 4 to 8, preferably about 5 to 7. Exemplary buffers include histidine, phosphate, Tris, citrate, succinate, and other organic acids. The buffer concentration may be, for example, about 1 mM to about 20 mM, or about 3 mM to about 15 mM, depending on the buffer and the desired isotonicity of the formulation (e.g., the reconstituted formulation). A preferred buffer is histidine, which has cryoprotective properties. Succinate is also a useful buffer.

[0057] A lyoprotectant is added to the formulation prior to lyophilization. In a preferred embodiment, the lyoprotectant is a non-reducing sugar, such as sucrose or trehalose. The amount of lyoprotectant in the formulation prior to lyophilization is generally such that upon reconstitution the resulting formulation is isotonic, although hypertonic reconstituted formulations may also be appropriate. Furthermore, the amount of lyoprotectant should not be so low that an unacceptable amount of protein degradation / aggregation occurs upon lyophilization.

[0058] When the lyoprotectant is a sugar (such as sucrose or trehalose) and the protein is an antibody, an exemplary concentration of the lyoprotectant in the formulation before lyophilization is about 10 mM to about 400 mM, preferably about 30 mM to about 300 mM, and most preferably about 50 mM to about 100 mM.

[0059] The ratio of protein to lyoprotectant is selected for each combination of protein and lyoprotectant. When an antibody is selected as the protein and a sugar (e.g., sucrose or trehalose) is used as the lyoprotectant to produce a high-protein-concentration isotonic reconstituted formulation, the molar ratio of lyoprotectant to antibody may be about 100 to about 1,500 moles of lyoprotectant per mole of antibody, preferably about 200 to about 1,000 moles of lyoprotectant per mole of antibody, and may be about 200 to about 600 moles of lyoprotectant per mole of antibody.

[0060] In a preferred embodiment, it has been found desirable to add a surfactant to the formulation prior to lyophilization. Alternatively, or in addition, a surfactant may be added to the lyophilized and / or reconstituted formulation. Exemplary surfactants include polysorbates (e.g., polysorbate 20 or 80), poloxamers (e.g., poloxamer 188), Triton, sodium dodecyl sulfate (SDS), sodium lauryl sulfate, sodium octyl glycoside, lauryl-, myristyl-, linoleyl-, or stearyl-sulfobetaine, lauryl-, myristyl-, linoleyl-, or stearyl-sarcosine, linoleyl-, myristyl-, or cetyl-betaine, lauroamidopropyl-, cocamidopropyl-, linoleamidopropyl-, myristamidopropyl-, palmidopropyl-, or isostearamidopropyl-betaine (e.g., lauroamidopropyl), myristamidopropyl-, palmidopropyl-, or isostearamidopropyl-dimethylamine, sodium methyl cocoyl, or disodium methyl oleyl taurate, and the MONAQUAT™ series (Mona Examples of surfactants include nonionic surfactants such as polyisoprene (Polyesterol), polyethyl glycol, polypropyl glycol, and copolymers of ethylene glycol and propylene glycol (e.g., Pluronics®, PF68, etc.). The amount of surfactant added is an amount that reduces aggregation of the reconstituted protein and minimizes particle formation after reconstitution. For example, the surfactant may be present in the formulation before lyophilization in an amount of about 0.001-0.5%, preferably about 0.005-0.05%.

[0061] A mixture of a lyoprotectant (such as sucrose or trehalose) and a bulking agent (such as mannitol or glycine) may be used to prepare the formulation before lyophilization. The bulking agent allows for the production of a uniform lyophilized cake without excessive pockets.

[0062] Other pharmaceutically acceptable carriers, excipients, or stabilizers, such as those described in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980), may be included in the pre-lyophilized formulation (and / or the lyophilized and / or reconstituted formulations) so long as they do not adversely affect the desired properties of the formulation. Acceptable carriers, excipients, or stabilizers are non-toxic to the recipient at the dosages and concentrations used, and include alternative buffers, preservatives, cosolvents, antioxidants (e.g., ascorbic acid, methionine), chelating agents (e.g., EDTA), metal complexes (e.g., Zn-protein complexes), biodegradable polymers (e.g., polyesters), and / or salt-forming counterions (e.g., sodium).

[0063] The pharmaceutical compositions and formulations described herein are preferably stable to maintain physical and chemical stability and integrity during storage. Various analytical techniques for measuring protein stability are available in the art and are reviewed in Peptide and Protein Drug Delivery, 247-301, Vincent Lee Ed., Marcel Dekker, Inc., New York, NY, Pub. (1991); Jones, A. Adv. Drug Delivery Rev. 10:29-90 (1993). Stability may be measured at a selected temperature for a selected period of time.

[0064] Formulations to be used for internal administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes, prior to or after lyophilization and reconstitution. Alternatively, sterility of the entire mixture can be achieved by autoclaving the components, excluding the protein, at about 120°C for about 30 minutes.

[0065] After mixing the protein, lyoprotectant, and other optional ingredients, the formulation is lyophilized. Various lyophilizers are available for this purpose, such as the Hull 50® (Hull, USA) or GT20® (Leybold-Heraeus, Germany) lyophilizers. Lyophilization is achieved by freezing the formulation and then sublimating the ice from the frozen contents at a temperature suitable for primary drying, where the product temperature is below the eutectic point or collapse temperature of the formulation.

[0066] Typically, shelf temperatures for primary drying range from about -30 to 25°C at appropriate pressures (typically about 50 to 250 mTorr) (assuming the product remains frozen during primary drying). The time required for drying depends primarily on the formulation, its size, type, and amount of liquid in the container (e.g., glass vial) holding the sample, and can range from a few hours to several days (e.g., 40 to 60 hours). The secondary drying step may be performed at about 0 to 40°C, depending primarily on the type and size of the container and the type of protein used. For example, shelf temperatures throughout the moisture removal stage of lyophilization may be about 15 to 30°C (about 20°C). The time and pressure required for secondary drying are those that produce a suitable lyophilized cake, depending, for example, on temperature and other parameters. The secondary drying time depends on the desired moisture level in the product and typically takes at least about 5 hours (e.g., 10 to 15 hours). The pressure may be the same as that employed in the primary drying step. Lyophilization conditions may vary depending on the formulation and vial size.

[0067] In some cases, it may be desirable to lyophilize the protein formulation in the container in which the protein will be reconstituted to avoid a transfer step. In this case, the container may be, for example, a 3, 5, 10, 20, 50, or 100 cc vial. As a general proposition, lyophilization results in a lyophilized formulation with a moisture content of less than about 5%, preferably less than about 3%.

[0068] At a desired stage, typically when the protein is to be administered to a patient, the lyophilized formulation may be reconstituted with a diluent, preferably such that the protein concentration in the reconstituted formulation is similar to the protein concentration in the pre-lyophilized formulation.

[0069] Reconstitution is typically performed at a temperature of about 25°C to ensure complete hydration, although other temperatures may be used as desired. The time required for reconstitution depends, for example, on the type of diluent, the amount of excipients, and the amount of protein. Exemplary diluents include sterile water, bacteriostatic water for injection (BWFI), a pH buffer (e.g., phosphate-buffered saline), sterile saline, Ringer's solution, or dextrose solution. The diluent optionally contains a preservative. Exemplary preservatives are described above, with aromatic alcohols such as benzyl alcohol or phenol alcohol being preferred preservatives. The amount of preservative used is determined by evaluating different preservative concentrations for compatibility with the protein and testing the effectiveness of the preservative. For example, if the preservative is an aromatic alcohol (e.g., benzyl alcohol), it may be present in an amount of about 0.1-2.0%, preferably about 0.5-1.5%, and most preferably about 1.0-1.2%.

[0070] Alternatively, a non-lyophilized formulation may be used that includes a binder and any of the well-known carriers, excipients, buffers, stabilizers, preservatives, adjuvants, and other additives described herein and well known in the art.

[0071] (Dosage and Administration) The above-described formulations may be administered to a subject (e.g., a human) in need of treatment by any suitable route, such as intravenous, intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intradermal, intra-articular, intrasynovial, intrathecal, intradermal, intratumoral, intranodal, intramedullary, oral, inhalation, or topical routes of administration, or by oral, inhalation spray, topical, rectal, nasal, buccal, vaginal, or implanted reservoir, in each case as a bolus dose or by continuous infusion over a period of time, or by an injectable depot route of administration, such as using 1, 3, or 6 month depot injectable or biodegradable materials and methods.

[0072] Commercially available nebulizers for liquid formulations, such as jet nebulizers and ultrasonic nebulizers, are useful for administration. Liquid formulations may be directly nebulized, or lyophilized powders may be nebulized after reconstitution. Alternatively, antibodies may be aerosolized using fluorocarbon formulations and metered-dose inhalers, or inhaled as lyophilized and milled powders. When CARs are used in the present invention, compositions of immune effector cells (e.g., T cells, NK cells) may be injected directly into tumors, lymph nodes, or sites of infection, or elsewhere.

[0073] The subject treated by the methods described herein may be a mammal, more preferably a human, including but not limited to farm animals, sport animals, pets, primates, horses, dogs, cats, mice, and rats.

[0074] An "effective amount" refers to the amount of an active ingredient, alone or in combination with one or more other active ingredients, required to confer a therapeutic effect on a subject. The effective amount will vary depending on the particular condition being treated, the severity of the condition, individual patient parameters such as age, physical condition, size, sex, and weight, the duration of treatment, the characteristics of concurrent treatments (if any), the particular route of administration, and similar factors, all of which are well known to those skilled in the art and can be addressed with no more than routine experimentation. In general, it is preferable to use the maximum dose of the individual ingredients or combinations thereof, i.e., the maximum safe dose according to reasonable medical judgment. Lower or tolerated doses may be appropriate for medical, psychological, or other reasons.

[0075] Empirical considerations such as the half-life of the antibody generally contribute to determining the dosage. For example, antibodies compatible with the human immune system, such as humanized antibodies or fully human antibodies, may be used to extend the half-life of the antibody and prevent it from being attacked by the host's immune system. The frequency of administration may be determined and adjusted over the course of treatment, and is generally, but not necessarily, determined based on the treatment and / or inhibition and / or amelioration and / or delay of gastric cancer. Alternatively, sustained-release formulations of the antibody may be appropriate. Various formulations and devices for achieving sustained release are known in the art.

[0076] In one example, dosages of the antibodies described herein may be empirically determined in individuals who have received one or more doses of the antibody. The individual may receive incremental doses of the antibody. Disease indicators (e.g., tumor growth) may be followed according to routine methods to assess the efficacy of the antibody.

[0077] Generally, for administration of any of the antibodies described herein, initial candidate dosages may be estimated from the studies described below. For repeated administration over several days or longer, depending on the condition, treatment is continued until desired symptom inhibition occurs or until therapeutic levels sufficient to alleviate the cancer are reached. An exemplary dosing regimen involves an initial high dose, followed by a lower maintenance dose. However, other dosing regimens may be useful depending on the pharmacokinetic decay pattern the physician seeks to achieve. For example, dosing may be administered once to four times per week. In some embodiments, the dosing frequency is once per week, once every two weeks, once per four weeks, once per five weeks, once per six weeks, once per seven weeks, once per eight weeks, once per nine weeks, or once per ten weeks, or monthly, once every two months, or once every three months, or more. The progress of this therapy can be easily monitored by conventional techniques and assays. The dosing regimen (including the antibody used) may vary over time.

[0078] Depending on the goal of treatment and the site of cancer, conventional methods known to those skilled in the medical arts may be used to administer the pharmaceutical composition to a subject.

[0079] Injectable compositions may contain a variety of carriers, such as vegetable oils, dimethylactamide, dimethylformamide, ethyl lactate, ethyl carbonate, isopropyl myristate, ethanol, and polyols (such as glycerol, propylene glycol, and liquid polyethylene glycol).

[0080] For intravenous injection, water-soluble antibodies may be administered by infusion, where a pharmaceutical formulation containing the antibody and a physiologically acceptable excipient, such as 5% dextrose, 0.9% saline, Ringer's solution, or other suitable excipient, is infused.

[0081] Intramuscular formulations, for example, a sterile preparation of a suitable soluble salt form of the antibody may be administered dissolved in a pharmaceutical excipient such as water for injection, 0.9% saline, or 5% glucose solution.

[0082] In one embodiment, the antibody is administered by a site-specific or targeted local delivery technique. Examples of site-specific or targeted local delivery techniques include various implantable depot sources or local delivery catheters (such as infusion catheters, indwelling catheters, or needle catheters), synthetic grafts, adventitial wraps, shunts and stents or other implantable devices, site-specific carriers, direct injection, or direct application of the antibody. See, e.g., International Patent Publication No. WO 00 / 53211 and U.S. Patent No. 5,981,568.

[0083] Another embodiment of the present disclosure provides an article of manufacture containing any of the pharmaceutical compositions and formulations described herein (e.g., comprising an antibody or binding agent) and providing instructions for its use and / or reconstitution. The article of manufacture includes a container. Suitable containers include, for example, bottles, vials (e.g., dual-chamber vials), syringes (e.g., dual-chamber syringes), and test tubes. The container may be formed from a variety of materials, such as glass or plastic. The container holds the formulation, and a label on or associated with the container may provide instructions for reconstitution and / or use. For example, the label may indicate that the formulation is to be reconstituted to a particular protein concentration. The container holding the formulation may be a multi-use vial, allowing for repeated administration (e.g., 2-6 administrations) of the reconstituted formulation. The article of manufacture may further include a second container containing a suitable diluent (e.g., BWFI). Upon mixing the diluent with the lyophilized formulation, the final protein concentration of the reconstituted formulation is generally at least 50 mg / mL. The article of manufacture may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, package inserts with instructions for use, and the like.

[0084] (Example) The following examples are not limiting and are merely illustrative. Unless otherwise noted, all cell lines were purchased from the American Type Culture Collection (ATCC, Manassas, VA), and all secondary antibodies used for detection were purchased from Jackson ImmunoResearch Laboratories (West Grove, PA). DNA and RNA manipulations were performed using standard methods as described in Sambrook et al., Molecular cloning: A laboratory manual; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989. Unless otherwise noted, all commercially available reagents and kits were used according to Mecker's instructions.

[0085] To explore target-specific antibodies for cancer therapy, we used live-cell immunization (LCI) and live-cell high-throughput screening (HTS) techniques to generate antibodies that specifically target human tumor surface antigens, and combined proteomics and molecular biology techniques to identify the targets.

[0086] Example 1: Generation and characterization of MAb11-22.1 mAb that specifically targets AML cell lines To obtain mAbs against conformational epitopes on cell surface antigens, a mixture of two human AML cell lines, MV4-11 and THP-1, in phosphate-buffered saline (PBS) was used for LCI and LC-HTS, as previously described (see International Patent No. WO2014146487A1, International Patent No. WO2017114204, U.S. Patent Publication No. 20210139602A1; Li et al., PLoS One. 2013, 8:e77398). Hybridoma culture supernatants were screened for interaction with the mixture of two live AML cell lines by fluorescence-activated cell sorting (FACS) assays using a BD FACSCalibur™ flow cytometer and high-throughput sampler (HTS), counterscreened with human peripheral blood mononuclear cells (PBMCs) provided by a healthy adult (Stanford Blood Center, Palo Alto, CA). Data were analyzed using FlowJo™ software (Becton Dickinson, San Jose, CA). Hybridoma colonies that showed strong and specific binding to the human AML cell lines but no binding to human PBMCs were selected for expansion, withdrawal from conditioned medium, and subcloning according to standard procedures (Kohler & Milstein, Nature 1975, 256:495-497; Winter & Milstein, Nature 1991, 349:293-299). For further characterization, monoclonal antibodies (mAbs) produced by these colonies were purified using MabSelect™ SuRe™ LX Protein A resin (GE Healthcare, Marlborough, Massachusetts).

[0087] The mAb, designated MAb11-22.1 mAb, showed high binding activity to nearly all nine human AML cell lines tested, but not to human PBMCs (Figure 1A, left panel). The binding signal was particularly high for NB4 cells, an AML M3 subtype cell line, followed by Kasumi-1 and HL-60 cell lines. To ensure that binding was not mediated by interaction of the mAb with Fc receptors (FcRs) on the AML cell surface, human TruStain FcX™ Fc Receptor Blocking Solution (Biolegend, San Diego, CA) was used in the FACS assay. Because the isoform of MAb11-22.1 mAb was IgG1 / κ as determined by the IsoStrip™ Mouse Monoclonal Antibody Isotyping Kit (Roche Molecular Systems, Pleasanton, CA), an irrelevant IgG1a / κ mouse antibody that does not interact with AML cell lines was used as a negative control (isotype control antibody; Figure 1A, right panel), confirming that the interaction of MAb11-22.1 mAb with the AML cell surface was specifically mediated by the variable region of MAb11-22.1 mAb.

[0088] To visualize the binding of MAb11-22.1 mAb to the surface of AML cells, we performed an immunocytochemistry (ICC)-based cell surface antibody binding assay. Cultured AML cells were fixed to glass slides in 4% paraformaldehyde using Cytospin 4 (Thermo Fisher Scientific, Waltham, MA). After heat-induced antigen retrieval, cells were blocked with goat serum (MilliporeSigma, St. Louis, MO) and then incubated with MAb11-22.1 mAb or an isotype control antibody for 1 hour, followed by a 1:1000 dilution of peroxidase-conjugated AffiniPure goat anti-mouse IgG (subclasses 1+2a+2b+3), Fcγ fragment-specific antibody (anti-Mo IgG Fc-HRP pAb, Jackson ImmunoResearch Laboratories). Cells were stained with 3,3'-diaminobenzidine (DAB) and counterstained with hematoxylin. As shown in Figure 1B, ICC assays confirmed that the target of MAb11-22.1 mAb was located on the surface of NB4 and THP-1 cells. The intensity of DAB staining on the NB4 cell surface was much higher than that on the THP-1 cell surface, and this correlated with the mean fluorescence intensity (MFI) in the FACS assay (Figure 1A, left panel).

[0089] Furthermore, Western blots of multiple AML cell lysates simultaneously probed with MAb11-22.1 mAb and mouse anti-human / mouse β-actin mAb (anti-β-actin mAb, Proteintech Group, Rosemont, IL) at 5 μg / mL each, followed by detection with a 1:20,000 dilution of anti-Mo IgG Fc-HRP pAb, revealed a common band of approximately 250 kDa under non-reducing conditions and a faint band of approximately 110 kDa under reducing conditions (Figure 1C). Whole-cell lysates of the acute lymphocytic leukemia (ALL) cell line Raji also showed a blot at the same position, albeit at a lower intensity. In contrast, MAb11-22.1 mAb did not detect any bands in Chinese hamster ovary (CHO) cell lysates (Figure 1C) or human PBMC cell lysates (data not shown) by Western blot analysis. The relative intensities of these hybridizing protein bands in AML cells were consistent with the MFI of the FACS assay (Fig. 1A) and the intensity of ICC staining (Fig. 1B), indicating that this protein is likely the target of MAb11-22.1 mAb.

[0090] Example 2: Identification and validation of human transferrin receptor 1 (TfR1) as the target of MAb11-22.1 mAb AML cell lysates were prepared in IP lysis buffer (Thermo Fisher Scientific) according to the manufacturer's instructions. Dynabeads™ Protein A for Immunoprecipitation (Thermo Fisher Scientific) were incubated with 50 μg of MAb11-22.1 mAb or isotype control antibody in PBS for 30 minutes at room temperature (RT). The antibody-bound Dynabeads™ were washed and incubated with each cell lysate for 30 minutes at RT, then washed sequentially with 0.5% Triton X-100 / PBS and PBS buffer. The immunoprecipitated (IP) proteins and antibodies were separated from the beads in 4x Laemmli denaturing sample buffer containing 2-mercaptoethanol and heated at 95°C for 5 minutes. Proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and stained with the ProteoSilver™ Silver Stain Kit (MilliporeSigma) according to the manufacturer's instructions. Silver staining revealed a single protein band in the IP sample with the same molecular weight as the Western blot (Figure 2A). The band was excised from the gel and digested with trypsin. Liquid chromatography-tandem mass spectrometry (LC-MS / MS) by BGI Americas Corporation (Cambridge, MA) identified TfR1 as the most abundant protein in the gel slice (#PSM = 32, coverage = 29.6%).

[0091] To confirm that TfR1 was the target of MAb11-22.1 mAb, recombinantly expressed human TfR1 extracellular domain with an N-terminal His tag (rTfR1-ECD, ACRO Biosystems, Newark, DE) was analyzed by SDS-PAGE under non-reducing conditions, along with whole-cell lysate samples from AML and ALL cells (positive control) and CHO cell lysate (negative control). Subsequently, Western blots were probed simultaneously with MAb11-22.1 mAb and anti-β-actin mAb (5 μg / mL each) as primary antibodies, and anti-Mo IgG Fc-HRP pAb (1:20,000) (Figure 2B). The results showed that MAb11-22.1 mAb could detect a single band of approximately 80 kDa, which correlates with the calculated molecular weight of 77.0 kDa for rTfR1-ECD. As shown in Figure 1C, Raji, NB4, OCI / AML2, and CHO cell lysates showed consistent results in reaction with MAb11-22.1 mAb.

[0092] To confirm the interaction between MAb11-22.1 mAb and rTfR1-ECD, a direct ELISA assay was performed. Immulon® microtiter plates (Thermo Fisher Scientific) coated with 0.1 μg / mL rTfR1-ECD were directly reacted with serial dilutions of MAb11-22.1 mAb, 6xHis His-Tag monoclonal antibody (anti-His mAb, Proteintech), or an isotype control antibody at RT for 1 hour, followed by a 1:2,000 anti-Mo IgG Fc-HRP pAb for 1 hour. 3,3',5,5'-tetramethylbenzidine (TMB) substrate was added, and the absorbance was measured at 450 nm using a SpectraMax microplate reader (Molecular Device, San Jose, CA). Figure 2C shows the direct interaction of 6His-tagged rTfR1-ECD with MAb11-22.1 mAb or anti-His mAb, but not with the isotype control antibody, demonstrating that TfR1 is the target of MAb11-22.1 mAb.

[0093] To further confirm that MAb11-22.1 mAb recognizes human TfR1, TFRC cDNA encoding the full-length TfR1 protein was amplified by reverse transcription-polymerase chain reaction (RT-PCR) from OCI / AML2 and THP-1 cells using a pair of primers (SEQ ID NO:11 and SEQ ID NO:12) ordered from Integrated DNA Technologies (Coralville, IA). The cDNA was fused in-frame to a DNA fragment encoding GFP at the C-terminus and then cloned into an in-house expression vector containing a human CMV promoter and a puromycin resistance gene (PuroR) for selection. CHO-DG44 cells that were not stained by MAb11-22.1 mAb by FACS were transfected with the TFRC-GFP expression plasmid and grown in EX-CELL® CD CHO serum-free medium (SFM) supplemented with puromycin. CHO cell colonies stably expressing high levels of EGFP were isolated and subcloned. CHO / rTfR1-GFP cells were stained with purified MAb11-22.1 mAb, anti-human TfR1 control mAb (R&D Systems, Minneapolis, MN), and two batches of isotype control antibody for 30 minutes at 4°C, followed by detection with R-phycoerythrin (PE)-conjugated AffiniPure goat anti-mouse IgG (subclasses 1+2a+2b+3) and an Fcγ fragment-specific pAb (anti-Mo IgG Fc-PE, Jackson ImmunoResearch). Results showed that, under FL1 (GFP) gating, CHO / rTfR1-GFP cells were stained by both MAb11-22.1 mAb and the anti-TfR1 control mAb, but both antibodies could bind to CHO cells without rTfR-GFP expression on the cell surface (Figure 2D). The IC of MAb11-22.1 mAb 50 The IC values ​​were 0.03–0.04 μg / mL, with the IC of the anti-TfR1 control mAb being approximately 0.1 μg / mL. 50Staining of CHO / rTfR-GFP cells with various GFP activities by MAb11-22.1 mAb showed a positive correlation between the MFI-PE and MFI-FITC values ​​(data not shown), demonstrating a direct interaction between MAb11-22.1 mAb and the extracellular domain of human TfR1. Forward primer: 5'-GAATGATGGATCAAGCTAGATCAGC-3' (SEQ ID NO: 11) Reverse primer: 5'-CTCATGGAAGCTATGGGTATCAC-3' (SEQ ID NO: 12)

[0094] Example 3: Measurement of binding affinity of MAb11-22.1 mAb to rTfR1-ECD The binding affinity of MAb11-22.1 mAb to the extracellular domain of TfR1 was determined using label-free biolayer interferometry (BLI) technology on an Octet® QK system (Molecular Devices, San Jose, CA). MAb11-22.1 mAb was immobilized on an anti-mouse IgG Fc capture (AMC) biosensor for 450 seconds, washed with kinetics buffer for 120 seconds, and then allowed to bind to rTfR1-ECD in serial dilutions for 450 seconds, followed by dissociation in kinetics buffer. Goat anti-mouse (H+L) Fab (Jackson ImmunoResearch) was used as a positive control for binding to MAb11-22.1 mAb. The assay was repeated with serial dilutions of rTfR1-ECD from 300 nM to 0.08 nM. No signal attenuation was observed even when the dissociation time was extended to 60 min (Fig. 3A, left panel) or the reaction temperature was increased to 37 °C (data not shown). Therefore, the interaction affinity between MAb11-22.1 mAb and rTfR1-ECD was very high, with a calculated K D The binding affinity of MAb11-22.1 mAb to anti-mouse (H+L) Fab was less than 1 pM (Fig. 3B). The binding of MAb11-22.1 mAb to anti-mouse (H+L) Fab showed a regular kinetic curve (Fig. 3A, right panel) and a fairly high affinity (K D= 1.04–1.45 nM) (Figure 3C), indicating that the extremely high affinity between MAb11-22.1 mAb and rTfR1-ECD was not an artifact.

[0095] Example 4: Competitive ELISA of MAb11-22.1 mAb and Transferrin for Binding to Human TfR1 A competitive ELISA was performed to determine whether MAb11-22.1 mAb binds to human TfR1, which overlaps with the Tf binding site. MAb11-22.1 mAb was directly labeled with HRP using the EZ-Link Maleimide-Activated HRP Kit (Thermo Fisher Scientific) according to the manufacturer's instructions. Immunlon microtiter plates were coated with 0.1 μg / mL rTfR1-ECD and incubated for 1 hour with 4-fold serial dilutions of HRP-conjugated MAb11-22.1 mAb, individually mixed with 2.5-fold serial dilutions of human Tf (MilliporeSigma) starting from 2 μg / mL. Various concentrations of Tf alone were added as a negative control. After extensive washing, TMB was added to detect binding of HRP-conjugated MAb11-22.1 mAb. After adding stop solution, absorbance was measured at 450 nm using a SpectraMax microplate reader.

[0096] Figure 4 shows that MAb11-22.1 mAb-HRP binds to rTfR1-ECD in a dose-dependent manner, regardless of the presence of Tf at various concentrations. Addition of up to 2 μg / mL (25 μM) of Tf did not significantly interfere with the binding of MAb11-22.1 mAb-HRP to rTfR1-ECD, suggesting that the Tf binding site does not overlap with the binding epitope of MAb11-22.1 mAb.

[0097] Example 5: FACS analysis of binding of MAb11-22.1 mAb to PBMCs and bone marrow (BM) cells Other researchers have reported that most anti-TfR1 antibodies interfere with Tf uptake and cause systemic hematologic toxicities, such as anemia, neutropenia, and leukopenia, in patients (CANDELARIA et al. Front. Immunol. 17 March 2021). To address safety concerns about MAb11-22.1 mAb as a potential treatment, we purchased multiple batches of fresh PBMCs from healthy donors from Stanford Blood Center (Palo Alto, CA) and frozen BM cells from healthy donors or AML patients from HumanCells Bioscience (Fremont, CA). Cells were washed with PBS and blocked with ice-cold PBS and 1% bovine serum albumin (BSA). The cells were stained with serial dilutions of MAb11-22.1 mAb and an isotype control antibody starting at 20 μg / mL at 4°C, followed by detection with 1:800 FITC- or PE-conjugated goat anti-Mo IgG Fc pAb (Jackson ImmunoResearch). Additionally, anti-human CD34-FITC (REAL487), anti-human CD233-PE (REA368), and anti-human CD235a-PE (REA1092) were purchased from Miltenyi Biotec (San Jose, CA), and the cells were simultaneously stained with MAb11-22.1 mAb.

[0098] FACS results showed that MAb11-22.1 mAb did not bind to normal PBMCs or normal BM cells, regardless of the mAb concentration used (Figure 5A). Consistent results were obtained for PBMCs and BM cells from different batches (donors) (data not shown). In contrast, BM cells from AML patients reacted with MAb11-22.1 mAb but not with the isotype control antibody (Figure 5B), suggesting that MAb11-22.1 mAb can distinguish between healthy and AML BM types. In healthy BM samples, more than 20% of cells were hematopoietic stem cells that could be stained with anti-human CD34 mAb-FITC (Figure 5C, left panel), whereas only a few cells reacted with MAb11-22.1 mAb and the isotype control antibody (Figure 5C, middle and right panels). Although TfR1 is generally considered a marker of nucleated red blood cells, neither CD233-positive red blood cells nor CD235a-positive red blood cells or erythroblasts reacted with MAb11-22.1 mAb (Figures 5D and 5E, left panels), suggesting that MAb11-22.1 mAb recognizes only TfR1 expressed on malignant cells and has a low risk of causing bone marrow suppression.

[0099] Example 6: Internalization assay of MAb11-22.1 mAb by tumor cells OCI / AML2, NB4, or Raji cells were plated in two 96-well culture plates at 1 × 10 in DMEM medium supplemented with 10% Gibco fetal bovine serum (FBS, Thermo Fisher Scientific). 5Cells were seeded at 100 cells / well and incubated for 1 hour at 4°C with MAb11-22.1 mAb, anti-CD20 mAb (R&D Systems), or isotype control mAb, serially diluted 1:10 starting at 10 μg / mL. Cells were centrifuged at 500 × g and washed twice with ice-cold PBS to remove unbound mAb. Cells from one 96-well plate were resuspended in warm medium and incubated at 37°C to allow mAb internalization, while cells from another plate were resuspended in ice-cold medium and incubated at 4°C to prevent antibody internalization. Samples were taken after 30 minutes, 1 hour, and 2 hours, washed twice with ice-cold PBS / 1% BSA, and then incubated for 30 minutes at 4°C with anti-Mo IgG Fc-FITC diluted 1:800. After washing three times with ice-cold PBS / 1% BSA, cells were resuspended in 150 μL of fixative containing 1% paraformaldehyde and stored in the dark in preparation for FACS analysis.

[0100] FACS results showed that MAb11-22.1 mAb bound to the surface of two AML cell lines, OCI-AML2 and NB4, in a dose-dependent manner at 4°C but was readily internalized at 37°C. Raji cells appear to have a very low copy number of TfR1 on their cell surface, yet they were able to internalize MAb11-22.1 mAb at 37°C (Fig. 6A, left panel). In contrast, anti-CD20 mAb bound only to Raji cells at 4°C, but not to AML cells, and was partially internalized by Raji cells at 37°C (Fig. 6A, middle panel). As expected, the isotype control antibody did not stain any of the three cell lines (Fig. 6A, right panel).

[0101] FACS-based internalization assays can only provide indirect evidence of endocytosis of antibody-antigen complexes and cannot distinguish between antibody internalization and antibody shedding. To directly observe mAb internalization, we performed a fluorescence microscopy-based internalization analysis using fluorescently labeled mAbs. Briefly, mAbs were labeled with CF488 dye using the Mix-n-Stain™ Antibody Labeling Kit (MilliporeSigma) according to the manufacturer's instructions. Cell binding was performed in ice-cold DMEM medium at 4°C for 1 hour in 96-well culture plates with different concentrations of mAb. After washing the cells twice with ice-cold PBS, one plate was incubated with warm DMEM at 37°C for 1 hour, while the other plate was resuspended in cold PBS and subjected to fluorescence imaging using a Keyence BZ-X800 all-in-one fluorescence microscope (Keyence, Itasca, IL). An isotype control antibody, labeled with CF488, was incubated with the cells in parallel as a negative control.

[0102] After 1 h of incubation at 4°C, MAb11-22.1 mAb-CF488 bound to the surface of OCI / AML2 cells, forming a high-intensity fluorescent ring that outlined the cells (Figure 6B, upper panel). The fluorescence intensity was proportional to the concentration of the mAb used. After 1 h of incubation at 37°C, most of the fluorescent signal moved from the cell surface to the interior space of the cells, suggesting that the surface-bound MAb11-22.1 mAb-CF488 molecules were primarily internalized by OCI / AML2 cells (Figure 6B, lower panel). This phenomenon was consistently observed in other AML cell lines, including NB4 and THP-1, at different concentrations of MAb11-22.1 mAb-CF488 (1, 0.5, 0.1, and 0.05 μg / mL) (data not shown). CF488-labeled isotype control antibody did not bind to any of the tested cells (Figure 6B, right panel).

[0103] Similar dose-dependent binding and internalization results were observed in MDA-MB-231 cells, a triple-negative breast cancer (TNBC) cell line, which reacted strongly with MAb11-22.1 mAb at 4°C, as revealed by FACS analysis. However, the fluorescent signal in MDA-MB-231 cells was much stronger than that in AML cells, as expected (Figure 6C). Furthermore, partial internalization occurred even at 4°C, and the majority of MAb11-22.1 mAb-CF488 molecules were internalized after 1 h of incubation at 37°C, suggesting that TfR1 protein expressed on the MDA-MB-231 cell membrane is highly prone to internalization upon binding with MAb11-22.1 mAb.

[0104] Example 7: In vitro effect of MAb11-22.1 mAb on proliferation of AML cell lines The effect of MAb11-22.1 mAb on the proliferation of AML cell lines was assessed in a cell-based in vitro assay. Cell viability was determined using a Cell Counting Kit-8 (CCK-8, Dojindo Molecular Technologies, Rockville, MD) according to the manufacturer's protocol. Briefly, AML cells grown in DMEM / 10% FBS and 100 μg / mL of MAb11-22.1 mAb or an isotype control antibody were plated at 5 × 10 cells per well in seven 96-well cell culture plates. 3 Cells / well were seeded in triplicate and incubated at 37°C in a humidified atmosphere of 5% CO2. Every 24 hours, cells were incubated with 10 μL / well of CCK-8 solution for 4 hours, followed by OD 450 Cell viability was assessed by measuring the .

[0105] As shown in Figure 7, both groups of OCI / AML2 cells continued to grow, but the proliferation rate of MAb11-22.1 mAb-treated cells was much lower than that of cells treated with an isotype control antibody (P<0.05). Similar data were obtained with other AML cell lines (data not shown). Therefore, although MAb11-22.1 mAb was able to partially inhibit the proliferation of OCI / AML2 cells, the mAb itself was not a strong therapeutic candidate. In fact, MAb11-22.1 mAb showed no effect in preliminary in vivo studies using the CLDX mouse model. MAb11-22.1 mAb has extremely high affinity for human TfR1 and showed a strong tendency for internalization by cancer cells, indicating its great potential for development as an ADC for cancer therapy.

[0106] Example 8: Sequencing of variable region cDNA of MAb11-22.1 hybridoma cDNA encoding the variable regions of the light (VL) and heavy (VH) chains of MAb11-22.1 mAb was amplified from total RNA of MAb11-22.1 hybridoma cells by 5'-rapid amplification of cDNA ends (5'-RACE) using the SMARTer RACE 5' / 3' kit (Takara Bio USA, San Jose, CA). The 5'-RACE primers are shown as SEQ ID NOs: 13 and 14. The cDNA fragments were amplified with Q5® High-Fidelity DNA polymerase and cloned into the pMiniT2.0 vector (New England Biolabs, Ipswich, MA) according to the manufacturer's protocol. Ten E. coli colonies from each transformant were randomly selected for plasmid purification using the Rapid Mini Plasmid Kit (IBI Scientific, Dubuque, IA) and Sanger DNA sequencing (Genewiz, South San Francisco, CA). All sequences were confirmed for V domain uniqueness by BLAST search at https: / / blast.ncbi.nlm.nih.gov / Blast.cgi and the international ImMunoGeneTics (IMGT) information® (http: / / www.imgt.org). The consensus sequences for the VL and VH of MAb11-22.1 mAb are shown in the disclosure as SEQ ID NO: 1 and SEQ ID NO: 3, respectively. The encoded amino acid sequences are shown as SEQ ID NO: 2 and SEQ ID NO: 4, respectively. Light chain primer: 5'-CTGCTCACTGGATGGTGGGAAGATGG-3' (SEQ ID NO: 13) Heavy chain primer: 5'-AGCTGGGAAGGTGTGCACAC-3' (SEQ ID NO: 14)

[0107] Construction and expression of chimeric MAb11-22.1 Ab (cAb): The VL and VH genes of MAb11-22.1 mAb were PCR amplified from the sequenced plasmid using the primer pairs shown in SEQ ID NOs: 15 to 18. The PCR fragments were digested with SpeI-NarI (VL) or XbaI-NheI (VH) restriction enzymes (New England Biolabs) and ligated in-frame with the constant regions of the human kappa light chain (CL) or human IgG1 heavy chain (CH1-CH3) carried in an in-house expression vector containing the mouse CMV promoter and the human CMV IE1 promoter, respectively, controlling the expression of the light and heavy chains. LV PCR forward primer: 5'-AGCACTAGTGCCGCCACCATGGAATCACAGACTCAGG-3' (SEQ ID NO: 15) LV PCR reverse primer: 5'-CTGGGCGCCGCTACAGTCCGTTTCAGCTCCAGCTTGG-3' (SEQ ID NO: 16) HV PCR forward primer: 5'-AGCTCTAGAGCCGCCACCATGGAGACAGACACACTCCTG-3' (SEQ ID NO: 17) HC PCR reverse primer: 5'-GCCTTTGGTGCTAGCAGAGACAGTGACCAGAGTC-3' (SEQ ID NO: 18)

[0108] After confirmation by DNA sequencing, the expression plasmid was transfected into Dux-1S-HD cells, an in-house developed CHO-DG44 derivative capable of growing to high density in EX-CELL® CD CHO SFM, using FectoPro transfection reagent (Polyplus-SA, Illkirch, France) according to the manufacturer's instructions. Transient expression and secretion of MAb11-22.1 cAb in EX-CELL® CD CHO SFM was verified by FACS analysis for binding to AML cell lines followed by affinity purification on MabSelect™ SuRe™ Protein A resin (GE Healthcare).

[0109] Example 9: Characterization of MAb11-22.1 cAb The purified cAb showed similar characteristics to its mAb counterpart in analyses such as SDS-PAGE, ELISA, and FACS (data not shown). The binding kinetics between MAb11-22.1 cAb and rTfR1-ECD was also determined using an Octet® QK system. MAb11-22.1 cAb was immobilized for 450 seconds using an anti-human IgG Fc capture (AHC) biosensor, and goat anti-human (H+L) Fab (Jackson ImmunoResearch) was used as a system control for binding to MAb11-22.1 cAb. The concentrations of rTfR1-ECD ranged from 50 nM to 1.28 nM using a 2.5-fold serial dilution. For MAb11-22.1 mAb shown in Figures 3A-3C, the dissociation (K) of MAb11-22.1 cAb was measured. off ) was not detected within 60 minutes of observation, indicating that the affinity of MAb11-22.1 cAb with rTfR1-ECD was extremely high (K D <1 pM, Figure 8A). Binding of MAb11-22.1 cAb to anti-human (H+L) Fab showed a regular kinetic curve, as expected, with a K D was 2.18 nM (Fig. 8B).

[0110] Example 10: In vitro effect of MAb11-22.1-S239C-DM1 on cancer cell lines Although MAb11-22.1 mAb lacked potent cytotoxic activity, its extremely high affinity for human TfR1 and high tumor specificity made it an excellent ADC candidate for cancer therapy. To investigate its potential use as an ADC drug, cysteine ​​scanning was performed on surface-exposed residues in the light and heavy chain constant regions of MAb11-22.1 cAb to investigate the antitumor effects of site-specific conjugation of various payloads. Site-directed mutagenesis was performed to replace the serine 239 codon (TCC) with a cysteine ​​codon (TGC) in the heavy chain Fc region of MAb11-22.1 cAb using the primer pair shown in SEQ ID NOs: 19 and 20. Transiently expressed MAb11-22.1-S293C cAb mutant was purified using MabSelect™ SuRe™ Protein A resin. As described by Junutula et al. (Nat Biotechnol. 26:925-932, 2008), the cysteine ​​or glutathione conjugated to Cys239 of MAb11-22.1-S293C cAb was removed from the culture medium by treatment with a 10-fold molar excess of dithiothreitol (DTT) in PBS at room temperature. The antibody was refolded to expose the free thiol group at S239C, and the integrity of the cAb was analyzed by SDS-PAGE. Site-specific conjugation was performed by reacting DM1 with the free thiol group at Cys239 in PBS with slow stirring at room temperature for 10–60 min to generate MAb11-22.1-S293C-DM1, which conferred ADC activity with a theoretical drug-antibody ratio (DAR) of 2. Free DM1 was removed by diafiltration three times against 10 volumes of PBS using an Amicon® stirred-cell reservoir equipped with a 30-kDa NMW ultrafiltration disk (MilliporeSigma). MAb11-22.1-S293C-DM1 was then filter-sterilized using a 0.2 μm syringe filter (VWR International, Radnor, PA). To exclude the effects of non-site-specific binding, the unmutated MAb11-22.1 cAb and an isotype control antibody were also treated with DM1 in parallel as negative controls.The integrity and binding capacity of DM1-treated antibodies were analyzed using SDS-PAGE, ELISA, and FACS. Endotoxin was analyzed using the Pierce™ Chromogenic Endotoxin Quantitation Kit (Thermo Fisher). No significant differences were observed between MAb11-22.1 cAb-DM1 and MAb11-22.1-S239C-DM1 in terms of binding affinity to TfR1 and cancer cell lines. As expected, MAb11-22.1-S239C-DM1 showed a slight delay in gel migration compared to untreated MAb11-22.1-S239C. S239C forward primer: 5'-AACTCCTGGGTGGACCT TGC GTGTTTCTGTTCCCCCCTAAGC-3' (SEQ ID NO: 19) S239C reverse primer: 5'-AACAC GCA AGGTCCACCCAGGAGTTCAGGAGCAGGGCAAGG-3' (SEQ ID NO: 20)

[0111] Representative cancer cell lines, including OCI / AML2 (AML subtype M4), Raji (ALL), HCC38 (TNBC), and MDA-MB-231 (TNBC), were cultured in DMEM / 10% FBS medium until they reached logarithmic growth phase. On day 0, baseline OD was measured by CCK-8 assay. 450 The optimal amount of each cell line was mixed with individual antibodies in triplicate in a 96-well cell culture plate to achieve a r = 0.4. Cells were incubated at 37°C in a 5% CO atmosphere. Cell proliferation was monitored by CCK-8 assay on days 3 and 5, respectively. An isotype control antibody without DM1 treatment reflected the baseline cell proliferation. In this study, MAb11-22.1-S239C and MAb11-22.1 cAb treated with or without DM1 were compared.

[0112] As shown in Figure 9, cell proliferation of all four cell lines was inhibited by MAb11-22.1-S239C-DM1 but not by untreated MAb11-22.1-S239C cAb. Wild-type MAb11-22.1 cAb had no apparent effect on cell proliferation, regardless of DM1 treatment. AML and ALL cell lines were highly sensitive to MAb11-22.1-S239C-DM1, as both 100 μg / mL and 300 μg / mL completely inhibited cell proliferation. Two TNBC cell lines were less sensitive to MAb11-22.1-S239C-DM1, as the 100 μg / mL concentration only partially inhibited cell proliferation.

[0113] Example 11: In vivo evaluation of MAb11-22.1-S239C-DM1 using an AML xenograft mouse model To evaluate the effect of MAb11-22.1-S239C-DM1 on AML tumor growth, a xenograft model was established using nu / nu mice. Six-week-old male athymic nude mice (Charles River Laboratories, Wilmington, MA) were injected subcutaneously into the right flank of the mice with 1.5 × 10 mAb cells dissolved in 0.1 mL of PBS. 6 OCI / AML2 cells were injected into the mice. Once all tumor nodules were visible, the mice were randomly divided into three groups (n = 5 or 6) and treated with MAb11-22.1-S239C-DM1 (low dose: 10 mg / kg b.wt, high dose: 20 mg / kg b.wt) or an isotype control antibody (without the S239C mutation) similarly treated with DM1 (20 mg / kg b.wt) by intraperitoneal (ip) injection once every four days for seven times (Q4 x 7). Tumor volume and body weight were measured every four days immediately before drug administration. Volume = 1 / 2 x (width) 2 The tumor volume was calculated using the formula: × length. 3 Animals were euthanized if the tumor volume exceeded 100 mg / kg or if the tumor became necrotic or ulcerated through the skin.

[0114] OCI / AML2 xenografts are an aggressive CLDX mouse model. Neither MAb11-22.1 mAb nor MAb11-22.1 cAb alone significantly delayed the growth of OCI / AML2 xenograft tumors (P > 0.05, data not shown). In the current study, 10 mg / kg b.wt (low dose) MAb11-22.1-S239C-DM1 resulted in complete regression and durable responses after one or two doses (Figure 10). Mice in the 20 mg / kg b.wt (high dose) MAb11-22.1-S239C-DM1-treated group (n = 6) showed different responses. Three mice, similar to the low-dose group, showed a 100% reduction in tumor volume after days 4 or 8; another mouse showed tumor regression on days 4 and 8 but subsequently experienced tumor regrowth; the remaining two mice did not respond to MAb11-22.1-S239C-DM1, and one mouse was euthanized on day 24 due to tumor progression. In the isotype control group (n=5), all tumors continued to grow, with two mice experiencing tumors reaching 2000 mm 3 Euthanasia was performed on day 20 because the body weight exceeded 100g. Despite the very high doses of ADC used, no systemic side effects such as changes in vital signs, loss of motor ability, appetite, or total body weight were observed during the study.

[0115] The significant effect of MAb11-22.1-S239C-DM1 on tumor growth compared with the isotype control confirmed that MAb11-22.1 cAb is a promising candidate for cancer therapeutic ADCs. Due to its high affinity and specificity for human TfR1, circulating MAb11-22.1-S239C accumulates in TfR1-positive tumor cells and delivers DM1 into the cells via endocytosis. In the presence of high concentrations of glutathione (GSH) within tumor cells, DM1 is released from the ADC, potentially exerting bystander killing effects on surrounding cells within xenograft tumors. This suggests that MAb11-22.1 ADCs may be applicable not only to hematological malignancies but also to solid tumors.

[0116] The mechanism underlying the variability in efficacy in the high-dose group is unclear. This may be due to the small sample size and individual differences in response to the compound due to differences in the expression levels of TfR1 on the tumor cell surface. Because high-dose ADC drugs can be rapidly eliminated or induce drug resistance, the dose range of MAb11-22.1-S239C-DM1 needs to be optimized. Nevertheless, given its high tumor specificity and antitumor efficacy data, MAb11-22.1 is an ideal anti-TfR1 antibody for ADC development. To achieve a consistent DAR and optimal dose range for cancer treatment, we are currently investigating potent payloads and ideal linker conjugation techniques for MAb11-22.1 ADCs.

[0117] The specific methods and compositions described herein are representative of preferred embodiments, are illustrative, and are not intended to limit the scope of the invention. Those skilled in the art will recognize other objects, aspects, and embodiments upon review of this specification, which are encompassed within the spirit of the invention as defined by the appended claims. It will be apparent to those skilled in the art that various substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention. The invention illustratively described herein can suitably be practiced in the absence of any element or limitation not specifically disclosed herein as essential. Thus, for example, in each example, embodiment, or example of the invention herein, the terms "comprise," "comprising," "containing," "having," and "have" shall be read expansively and without limitation as synonymous. The methods and processes illustratively described herein may suitably be practiced in different order of steps and are not necessarily limited to the order of steps set forth in the specification or claims.

[0118] Under no circumstances shall the invention be construed as limited to the particular examples or embodiments or methods specifically disclosed herein. Under no circumstances shall the invention be construed as limited by statements made by examiners or other officers or employees of the Patent and Trademark Office unless such statements have been specifically and without limitation expressly adopted in their entirety in an applicant's replying brief.

[0119] The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also forms part of the invention. The terms and expressions used herein are used for purposes of description and not limitation, and the use of such terms and expressions is not intended to exclude equivalents of the features shown and described or portions thereof, but it will be appreciated that various modifications are possible within the scope of the invention as claimed. Thus, while the invention has been specifically disclosed by preferred embodiments and optional features, it will be understood that those skilled in the art may employ modifications and variations of the concepts disclosed herein, and that such modifications and variations are deemed to be within the scope of the invention as defined by the appended claims.

[0120] (Incorporated by reference) All patents and patent applications cited herein are hereby incorporated by reference, as are all other references cited.

[0121] Commonly cited antibody-related patents include: U.S. Patent No. 7,317,091 B2 U.S. Patent No. 5,500,362 U.S. Patent No. 4,816,567 U.S. Patent No. 5,225,539 U.S. Patent Nos. 5,565,332; 5,580,717; 5,733,743; and 6,265,150 U.S. Patent No. 5,932,448 U.S. Patent No. 7,538,196 U.S. Patent No. 8,148,496 U.S. Patent No. 8,518,891 U.S. Patent No. 9,310,373 U.S. Patent No. 9,764,041 U.S. Patent No. 11,040,084 European Patent No. EP239400B1 International Patent No. WO00 / 53211 and U.S. Patent No. 5,981,568 International Patent No. WO2014146487A1 U.S. Patent Publication No. 20170151343 U.S. Patent Publication No. 20170335281 International Patent No. WO2017114204 U.S. Patent Publication No. 20210139602A1

[0122] The non-patent literature cited in the specification is listed below in author order. Bomford AB and Munro HN.Hepatology.(1985)5:870-875. Brooks D, Taylor C, Dos Santos B, Linden H, Houghton A, Hecht TT. Clin Cancer Res. (1995) 1:1259-1265. Callens, C, Moura IC, Lepelletier Y, Coulon S, Renand A, Dussiot M, Ghez D, Benhamou M, Monteiro RC, Bazarbachi A, and Hermine O. Leukemia. (2008)22:42-48. Candelaria PV,Leoh LS,Penichet ML,and Daniels-Wells TR.Front.Immunol.17 March 2021.doi.org / 10.3389 / fimmu.2021.607692 Daniels TR, Delgado T, Rodriguez JA, Helguera G, and Penichet ML. Clin Immunol. (2006) 121:144-158. Daniels TR,Ortiz-Sanchez E,Luria-Perez R,Quintero R,Helguera G,Bonavida B,Martinez-Maza O,and Penichet ML.J Immunother.(2011)34:500-508. Daniels-Wells TR,Candelaria PV,Emiko K,Wen J,Weng L,Kamata M,Almagro JC,Martinez-Maza O,and Penichet ML.Cancer Res.(2020)80(16 Suppl):5655. Daniels-Wells TR,Widney DP,Leoh LS,Martinez-Maza O,Penichet ML.J Immunother.(2015)38:307-310. Faulk WP,Hsi BL,Stevens PJ.Lancet.(1980)2:390-392. Feng R,Wang Y,Ramachandran V,Ma Q,May MM,Li M,Zhou JX,Xu X,Xu K,Fang S,Xia W,Sui D,Liu H,Gao Gatter KC,Brown G,Trowbridge IS,Woolston RE,Mason DY.J Clin Pathol.(1983)36:539-545. Jeong SM,Hwang S,Seong RH.Biochem Biophys Res Commun.(2016)471:373-379. Johnson M,El-Khoueiry A,Hafez N,Lakhani N,Mamdani H,Rodon J,Sanborn RE,Garcia-Corbacho J,Boni V,Stroh M,Hannah AL,Wang S,Castro H,Spira A.Clin Cancer Res.(2021)27:4521-4530. Junutula JR,Raab H,Clark S,Bhakta S,Leipold DD,Weir S,Chen Y,Simpson M,Tsai SP,Dennis MS,Lu Y,Meng YG,Ng C,Yang J,Lee CC,Duenas E,Gorrell J,Katta V,Kim A,McDorman K,Flagella K,Venook R,Ross S,Spencer SD,Lee Wong W,Lowman HB,Vandlen R,Sliwkowski MX,Scheller RH,Polakis P,Mallet W.Nat Biotechnol.(2008)26:925-932. Kohler & Milstein. Nature 1975;256:495-497 Lepelletier Y,Camara-Clayette V,Jin H,Hermant A,Coulon S,Dussiot M,Arcos-Fajardo M,Baude C,Canionni D,Delarue R,Brousse N,Benaroch P,Benhamou M,Ribrag V,Monteiro RC,Moura IC,Hermine O.Cancer Res.(2007)67:1145-1154. Li M, Gao J, Feng R, Wang Y, Chen X, Sun J, Zhang D, Zhu Z, Ellis LM, Lu M, Lee JE, Feng Z, Liu B. PLoS One.2013;8:e77398 Moura IC,Centelles MN,Arcos-Fajardo M,Malheiros DM,Collawn JF,Cooper MD,Monteiro RC.J Exp Med.(2001)94:417-425. Moura,IC,Y.Lepelletier,B.Arnulf,P.England,C.Baude,C.Blood.(2004)103:1838-1845. Nagai K,Nakahata S,Shimosaki S,Tamura T,Kondo Y,Baba T,Taki T,Taniwaki M,Kurosawa G,Sudo Y,Okada S,Sakoda S,Morishita K.Cancer Med.(2014)3:1085-1099. Neiveyans M,Melhem R,Arnoult C,Bourquard T,Jarlier M,Busson M,Laroche A,Cerutti M,Pugniere M,Ternant D,Gaborit N,Chardes T,Poupon A,Gouilleux-Gruart V,Pelegrin A,Poul MA.MAbs.(2019)11:593-605. Peer D,Karp JM,Hong S,Farokhzad OC,Margalit R,Langer R.Night Nanotechnol.(2007)2:751-760. Qian Z, LI H, SUN H, HO K. Pharmacol Rev. (2002) 54:561-5 Richardson DR,Kalinowski DS,Lau S,Jansson PJ,Lovejoy DB.Biochim.Biophys.Act Gen Subj.(2009)1790:702-717. Shimosaki S,Nakahata S,Ichikawa T,Kitanaka A,Kameda T,Hidaka T,Kubuki Y,Kurosawa G,Zhang L,Sudo Y,Shimoda K,Morishita K.Biochem Biophys Res Commun.(2017)485:144-151. Sutherland R,Delia D,Schneider C,,Newman R,Kemshead J,Greaves M.Proc Natl Acad Sci USA(1981)78:4515-4519. Trowbridge IS and Lopez F.Proc Natl Acad Sci U S A.(1982)79:1175-1179. Ward JH.Invest Radiol.(1987)22:74-83. Winter &Milstein.Nature 1991;349:293-299 Zhang L,Nomura F,Aikawa Y,Kurosawa Y,Morishita K,Sudo Y.Cancer Res.(2017)77(13 Suppl):5586.

Claims

1. A binding agent targeting TfR1 comprising a light chain variable region and conjugated to an anti-tumor agent, wherein CDR1-CDR3 have sequences at least 70% identical to SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, respectively.

2. 2. The binding agent complex of claim 1, wherein CDR1 to CDR3 of the light chain variable region have the same sequences as SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, respectively.

3. A binding agent that targets TfR1 conjugated to an anti-tumor agent, the binding agent having a light chain variable region that is at least 70% identical to SEQ ID NO:

2.

4. A binding agent targeting TfR1 comprising a heavy chain variable region conjugated to an anti-tumor agent, wherein CDR1 to CDR3 have sequences at least 70% identical to SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10, respectively.

5. The binding agent complex of claim 4, wherein CDR1 to CDR3 of the heavy chain variable region have the same sequences as SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10, respectively.

6. A binding agent that targets TfR1 conjugated to an anti-tumor agent, the binding agent having a heavy chain variable region that is at least 70% identical to SEQ ID NO:

4.

7. 3. An isolated DNA or RNA molecule encoding the light chain variable region of the binding agent of claim 2.

8. An isolated DNA molecule having the nucleotide sequence of SEQ ID NO:

1.

9. 6. An isolated DNA or RNA molecule encoding the heavy chain variable region of the binding agent of claim 5.

10. An isolated DNA molecule having the nucleotide sequence of SEQ ID NO:

3.

11. The binding agent conjugate of claim 1 , wherein the binding agent is a monoclonal antibody.

12. 12. The binding agent conjugate of claim 11, wherein the monoclonal antibody is a murine, human, humanized, chimeric, bispecific or multispecific antibody.

13. 12. The binding agent complex of claim 11, wherein the binding agent is a diabody, a single domain antigen binding (SDAB) molecule, a VH or VL domain, or a VHH domain.

14. The binding agent complex of claim 11 , wherein the monoclonal antibody has an IgG1 heavy chain and a kappa light chain.

15. The binding agent is Fab, Fab', F(ab') 2 , rIgG, Fv or Fd fragment.

16. The binding agent is an scFv or sc(Fv). 2 2. The binder complex of claim 1 , wherein

17. 12. The binding agent complex of claim 11, wherein the monoclonal antibody is of class IgD, class IgE, class IgG, class IgA or class IgM, or a subclass of one of the above classes.

18. 18. The binding agent complex of claim 17, wherein the subclass of the monoclonal antibody is IgG1, IgG2, IgG3, IgG4, IgA1 or IgA2.

19. 18. The binding agent complex of claim 17, wherein the monoclonal antibody has a kappa light chain.

20. A vector comprising the isolated DNA molecule of claim 8.

21. A binding agent targeting TfR1, having a light chain variable region in which CDR1-CDR3 comprise the sequences identical to SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, respectively.

22. A binding agent targeting TfR1, having a heavy chain variable region in which CDR1-CDR3 comprise the sequences identical to SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10, respectively.

23. A binding agent targeting TfR1, having a light chain with a sequence identical to SEQ ID NO:

2.

24. A binding agent targeting TfR1, having a heavy chain with a sequence identical to SEQ ID NO:

4.

25. 25. The binding agent of claim 24 having a light chain with a sequence identical to SEQ ID NO:2.

Citation Information

Patent Citations

  • Anti-transferrin receptor antibodies and methods using same

    WO2013103800A1

  • Antibody-drug conjugate

    WO2017221883A1